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Finding a nontoxic, effective means to purge the latent HIV-1 reservoir in virally suppressed 
individuals undergoing antiretroviral therapy (ART) remains a major obstacle to a functional cure.  
The ‘kick and kill’ approach to controlling HIV-1 involves induction of HIV-1 latency reversal 
(LR) during ART to expose infected cells, while creating an arsenal of immune effector cells, such 
as cytotoxic T lymphocytes (CTL), capable of eliminating these targets. While pharmacological 
latency reversal agents (LRAs) have achieved limited success in ex vivo studies, none have been 
shown to reduce the latent reservoir in HIV-1-infected individuals.  In addition, some LRAs have 
been shown to negatively impact antigen-specific CD8+ T cell effector responses in vitro.  An 
optimal cure strategy must address not only induction of proviral gene expression but also 
clearance of reactivated cells presenting HIV-1-associated peptide epitopes by either highly 
functional CTL, or through incorporation of other immune-based strategies, including broadly 
neutralizing antibodies, T cell vaccines, or compounds modulating pro-apoptotic pathways.  
Conventional dendritic cells (DC) have been safely and widely used in HIV-1 clinical trials for 
their capacity to induce antigen-specific T cell responses, but their HIV-1 LRA potential has been 
underexplored.  In this dissertation, I show that antigen-presenting monocyte-derived DC 
generated from chronic HIV-1-infected individuals on ART were shown to induce HIV-1 LR in 
autologous CD4+ T cells in an antigen-dependent manner.  The LRA activity of DC does not 
v 
appear to be a function of unidirectional communication from DC to CD4+ T cells, as DC-mediated 
LR was enhanced by bidirectional signaling events resulting from DC:CD4+ T cell cross-talk and 
sharply diminished by blockade of the CD40L/CD40 helper signaling pathway.  Importantly, these 
data demonstrate the potential of this DC-based therapeutic to promote both the antigen-specific 
exposure and CTL killing of exposed CD4+ T cells harboring replication-competent provirus.  Of 
public health significance, strategic inclusion of virus-associated MHC class II helper antigens in 
DC-based HIV-1 immunotherapies could serve both as a targeted means to safely unmask virus 
antigen-specific CD4+ T cells harboring HIV-1, and to support CTL responses that effectively 
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1.1 Mechanisms contributing to HIV-1 latency 
Despite major advances in human immunodeficiency virus-1 (HIV-1) treatment and prevention 
since the discovery of the virus in 1983 (1), the global rate of new infections remains constant at 
approximately 2 million per year (2, 3).  Although optimal antiretroviral therapy (ART) suppresses 
viremia to below the limit of detection of clinical assays, HIV-1 is managed as a chronic disease 
due to its persistence in a long-lived population of resting memory CD4+ T cells considered to be 
the major reservoir (4, 5).  Early treatment can limit reservoir size but not prevent its establishment, 
which occurs within days of initial infection (6).  A biphasic decay in productively infected cells 
follows ART initiation.  In the initial rapid phase, the majority of infected cells die with a half-life 
(t1/2) of <1 day due to viral cytopathic effects or lysis by HIV-specific cytotoxic T lymphocytes 
(CTL) (7-9).  A second population that may represent recently infected cells with unintegrated 
HIV (10) decays within a period of approximately 14 days (9).  The second slower decay phase is 
marked by the death of infected macrophages, dendritic cells (DC), and partially activated CD4+ 
T cells, which have a longer turnover rate (9).   Based on the decay kinetics of these compartments, 
it was initially predicted that 2-3 years of ART would be sufficient to eliminate all HIV-infected 
cells (9).  However, rebound of viremia to pretreatment levels in HIV-infected individuals who 
discontinued therapy provided evidence for a third long-lived population of infected cells (11). 
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HIV latency results from infection of activated CD4+ T cells that are either reverting to a 
resting memory state or undergoing an effector-to-memory transition (12).  During this rare 
window of opportunity, high CCR5 expression, adequate deoxynucleotide triphosphate (dNTP) 
pools, and sequestration of host transcription factors permit virus entry and integration but limit 
post-integration proviral gene expression, thus sparing these cells from viral cytopathic effects or 
effector-mediated clearance (12).  The existence of the latent HIV-1 reservoir was confirmed by 
the discovery that replication-competent virus could be induced from the resting memory CD4+ T 
cells HIV-infected individuals on long-term ART (13-15).  With a t1/2 of 44 months, this pool of 
infected cells would require approximately 73 years of therapy to eradicate (16).  As such, the 
latent reservoir of inducible, replication-competent HIV-1 in ART-suppressed individuals is 
considered a critical barrier to a cure (17), since the lack of viral protein expression in latently 
infected cells allows the reservoir to escape immune surveillance.  
Numerous mechanisms that would enable viral persistence during ART have been 
proposed.  For example, lack of expression of pro-apoptotic viral proteins or of retinoic acid-
inducible gene I (RIG-I)-mediated detection of viral RNA could promote survival of latently 
infected cells (18, 19).  In addition, compared to uninfected cells, increases in anti-apoptotic 
cellular proteins have been detected in latently HIV-infected cells (20-22).  Specifically, increases 
in the B cell lymphoma-2 (Bcl-2) protein promote elevated levels of antioxidant molecules that 
protect latently infected cells from oxidative stress-induced apoptosis (20), and increases in the X-
linked inhibitor of apoptosis (XIAP) protein counteract the protease activity of caspases 3, 7, and 
9 (21, 22).  Another study pointed to inhibition of pro-apoptotic cellular proteins as contributing 
to prolonged survival of HIV-infected Jurkat T cells (23).  
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It has also been shown that in HIV-infected individuals on suppressive cART, HIV-1 DNA 
preferentially integrates within actively transcribed host genes that regulate cell growth and 
division, thereby promoting viral persistence (24-26).  Integration into the introns of such genes 
fosters latency through several mechanisms of transcriptional interference that contribute to 
repression of the HIV-1 promoter (27), including enhancer trapping, convergent transcription, and 
promoter occlusion (4, 28, 29).  Enhancer trapping involves hijacking of the enhancer located 
within the 5’ HIV-1 LTR for use by a proximal cellular gene promoter, thus preventing its activity 
on viral transcription (27).  During convergent transcription, HIV-1 integrates in the opposite 
orientation of the host gene, potentially resulting in collision of elongation complexes initiating 
from the viral and cellular promoters and premature termination of transcription (4, 28).  Finally, 
promoter occlusion occurs when RNA polymerase from an upstream cellular promoter displaces 
transcription factors from a downstream HIV-1 promoter of the same transcriptional orientation, 
preventing assembly of the viral preinitiation complex (4, 30).   
In addition to the effects of viral integration site on proviral transcription, epigenetic 
silencing of HIV-1 gene expression also plays a significant role in the establishment and 
maintenance of latency through reversible modifications in chromatin structure (27).  Chromatin-
modifying enzymes regulate the four main mechanisms controlling DNA accessibility to 
transcription factors in the vicinity of the HIV-1 promoter, which is flanked by nucleosomes 
expressing repressive epigenetic marks in latently infected cells (29).  Histone deacetylases 
selectively deacetylate lysine residues in the histone tails of HIV-1 promoter heterochromatin, 
producing a closed chromatin state inaccessible to transcription factors, whereas histone 
acetyltransferases acetylate these residues, creating an open chromatin environment conducive to 
proviral transcription (27).  Trimethylation of histones in the HIV-1 LTR region by histone 
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methyltransferases also represses transcription (27), and methylation of CpG islands surrounding 
the HIV-1 transcription start site by DNA methyltransferases has been shown to completely silence 
the HIV-1 promoter (31, 32).  Indeed, the correlation between cART duration and degree of 
methylation of the HIV-1 promoter suggests a role for this mechanism in persistence of the latent 
reservoir (33).  Another factor contributing to repression of HIV-1 transcription during latent 
infection is sequestration of key cellular transcription factors, such as NF-κB, Sp-1, AP-1, and P-
TEFb; that remain in an inactive state in resting CD4+ T cells harboring the virus (27, 34, 35). 
To further complicate the quest for a cure, latently infected CD4+ T cells that may contain 
intact, replication-competent provirus can undergo clonal expansion due to homeostatic 
proliferation even during ART, thus slowing viral decay (25, 36-38).  HIV-1 integration occurs at 
numerous sites in the host genome, favoring actively transcribed genes that become activated upon 
HIV infection (26, 39, 40).  Analysis of integration site sequences is used to identify clonally 
expanded progeny arising from a single infected cell (25).  Since proviral/host junction sequences 
identify the location and orientation of HIV DNA integration, breakpoints in host DNA can be 
used to identify these integration sites in clonally expanded populations (25).  Longitudinal 
analyses of patient sequences have revealed that the proportion of persistent proviruses in 
proliferating cells increases with ART duration (37, 41) and that expanded clones can persist for 
several years (25).  Furthermore, integrations are concentrated in genes associated with cell 
growth, mitosis, and cancer (25, 37).  One study of five ART-treated individuals determined that 
40% of HIV integration sites were in clonally expanded cells, and 50% of the infected cells in one 
patient were derived from a single clone (25).  Some have reported that the majority of proliferating 
clonally expanded cells contain defective proviruses, while the replication-competent HIV-1 
reservoir is contained within a subset of CD4+ T cells characterized by single integration events 
5 
within transcriptionally silent regions of the genome (41).  However, Simonetti et al. identified a 
CD4+ T cell clone that contained infectious provirus and was highly enriched in cancer metastases 
in an HIV-infected individual with squamous cell carcinoma (36).  Recent ex vivo data showed 
that T cell clones harboring replication-competent HIV-1 either persist over a span of years in 
some virally suppressed individuals or emerge and wane (42). 
Although extensive evidence supports the lack of sequence evolution in the latent HIV-1 
reservoir due to successful ART (43-47), several controversial explanations for the stability of the 
latent reservoir in ART-treated patients have been proposed.  One report attributes continual 
replenishment of the reservoir during ART to ongoing, low level viral replication (48).  Potential 
variables permitting ne novo infection events include suboptimal drug penetration in tissue sites 
such as the lymph nodes (49, 50) and cell-to-cell spread of virus that is not easily blocked by ART 
(51).   Lorenzo-Redondo et al. reported ongoing HIV-1 replication in the lymphoid tissues of three 
cART-suppressed individuals, a phenomenon that has yet to be confirmed by other studies (27, 
50).  Importantly, this study purports that viral evolution is ongoing during suppressive ART based 
only on sequences analyzed during the first 6 months of ART, and the rapidly decaying population 
of infected cells that predominates during this period does not reflect the stable reservoir during 
chronic HIV infection (10, 52).  However, another group described proviruses with genetic and 
transcriptional signatures of active replication in lymph node T follicular helper (TFH) and non-
TFH subsets in elite controllers (53).  In support of these findings, persistent viral replication has 
also been reported in the B cell follicles of SIV-infected rhesus macaque elite controllers (54), and 
CXCR5+PD-1+ TFH  have been described as the major source of replication-competent, infectious 
HIV-1 among blood and lymph node memory CD4+ T cell populations in individuals on long-term 
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ART (55).  In short, the extent to which viral replication in anatomical sanctuaries poses a barrier 
to an HIV cure warrants further investigation. 
1.2 Methods to quantify the latent HIV-1 reservoir 
Only replication-competent proviruses capable of viral rebound in the absence of antiretroviral 
therapy pose a barrier to an HIV-1 cure (5, 14).  This subset of proviruses is defined as the latent 
HIV reservoir.  However, a complex and heterogeneous population of both replication-competent 
and defective proviruses exists within resting CD4+ T cells that harbor persistent virus (41, 56-63).   
Because persistent HIV-1 includes all forms of integrated proviral DNA in infected cells (64), 
methods of detection that cannot distinguish between these various forms prevent accurate 
quantification of the latent reservoir.  There is little correlation between PCR- and cell culture-
based assays commonly used to measure the latent reservoir, which complicates efforts to 
determine the efficacy of HIV eradication strategies (17). 
1.2.1  Culture-based assays  
The first method used to quantify the latent reservoir was the quantitative viral outgrowth assay 
(QVOA) (14, 65).  The QVOA is a limiting dilution assay that measures the frequency of resting 
CD4+ T cells that produce infectious virus after a single round of in vitro mitogenic stimulation 
with phytohemagglutinin (PHA) to induce maximum T cell activation.  Irradiated allogeneic 
PBMC are added to the culture to enhance PHA-induced T cell activation by acting as antigen-
presenting cells, and viruses released into the supernatant are expanded in culture for 2-3 weeks 
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by the addition of CD4+ lymphoblasts from HIV-negative donors (14, 65).  Culture supernatants 
are tested by ELISA for the presence of HIV-1 p24 antigen to detect exponential viral outgrowth 
(17, 57).  Virus in the supernatant can also be detected by ultrasensitive RT-PCR at day 7 post-
stimulation (66).  Limiting dilution analysis software employing maximum likelihood estimates 
(67) is used to calculate infectious units per million (IUPM) cells recovered from the QVOA. The 
QVOA detects only replication-competent HIV-1 induced after one round of mitogenic stimulation 
(induced proviruses), but underestimates the true size of the reservoir (17).  For example, viral 
outgrowth may not be detected in some wells that actually contain cells harboring intact provirus 
that might be activated after additional rounds of stimulation (noninduced proviruses), even though 
most noninduced proviruses are defective (57).  Indeed, <1% of replication-competent proviruses 
are induced by maximum T cell activation (57).  Thus, the QVOA estimates the frequency of 
replication-competent proviruses in ART-suppressed HIV-infected individuals to be 1 in 106 
resting CD4+ T cells, which is considered to be a ‘definitive minimal estimate’ (17, 56).  
Interestingly, sequencing analyses of intact viral genomes suggest that the true size of the latent 
reservoir is more likely 60/106 resting CD4+ T cells (57).  Furthermore, the QVOA also has 
numerous technical limitations.  In addition to the requirement for large blood volumes to isolate 
donor resting CD4+ T cells, the QVOA is labor intensive, time consuming, and expensive.  
Although these factors have prompted the development of simpler PCR-based methods of 
detection, the QVOA is still considered the gold standard for quantifying the latent reservoir.  
Importantly, the QVOA can detect individual latently infected cells, since clonal viruses that 
expand in wells cultured at limiting dilution can be sequenced (17). 
Variations of the QVOA have been devised, including the multiple stimulation viral growth 
assay (MS-VOA) (63), the latency clearance assay (LCA) (68, 69), and the murine viral outgrowth 
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assay (MVOA) (70).  The MS-VOA was developed in recognition of the finding that the QVOA 
underestimates the size of the latent reservoir, since latently infected cells can proliferate in 
response to mitogenic stimulation in the absence of virus production, but generate progeny cells 
that contain infectious noninduced proviruses (INPs) (63).  To increase the chances of detecting 
replication-competent proviruses that were not reactivated after one round of stimulation, three 
additional rounds of stimulation with PHA were added to the original assay format (63).  The LCA 
is a standard QVOA that incorporates autologous CTL for the purpose of demonstrating a 
reduction in the recovery of replication-competent virus resulting from effector-mediated 
elimination of exposed virus-expressing target cells (68).  Sung et al. utilized the LCA to 
demonstrate that the HDACi vorinostat can create sufficient viral antigen exposure in latently 
infected cells from aviremic individuals to allow clearance of these cells (69).  Reported to be more 
sensitive than the standard QVOA (71), the MVOA has also been utilized for the amplification of 
latent infectious virus (70).  In this assay, resting CD4+ T cells from virally suppressed HIV-
infected individuals are adoptively transferred into NOD-SCID IL-2Rγ-/- (NSG) humanized mice, 
and plasma viral RNA is monitored to detect viral rebound (70).   However, the MVOA is not a 
quantitative measurement of the latent reservoir, but rather a measure of residual viremia in 
peripheral blood (70).  Most recent in the development of more sensitive assays to accurately 
quantify inducible, replication-competent HIV-1 is the TZA (72).  The TZA utilizes the HIV-
permissive TZM-bl reporter cell line to demonstrate productive infection by reactivated HIV-1 
from latently infected resting CD4+ T cells of aviremic individuals on ART (72).  HeLa-derived 
TZM-bl cells express the HIV-1 receptor CD4, as well as CCR5 and CXCR4 coreceptors.  An 
integrated copy of the β-galactosidase (β-gal) gene under control of the HIV-1 promoter allows 
detection of infectious virus through chemiluminescent measurement of β-gal activity.  Fractional 
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provirus expression (fPVE) can be calculated as a function of IUPM divided by the total HIV-1 
DNA present in a sample (72).  Using this method, Sanyal et al. determined that the size of the 
inducible, replication-competent HIV-1 reservoir in ART-suppressed individuals is approximately 
70-fold larger than estimates obtained from the QVOA (72), in agreement with estimates based on 
sequence analysis of intact proviruses (57). 
Still other culture-based methods of measuring the latent reservoir rely on qRT-PCR-based 
quantification of different forms of viral RNA representing distinct stages of HIV-1 replication 
(17).  In these assays, maximally stimulated resting CD4+ T cells are plated at limiting dilution to 
include less than one virus-producing cell per well and cultured for 2-7 days.  Cell-associated (CA) 
multiply spliced mRNA represents transcripts that are produced early in HIV replication, whereas 
CA unspliced transcripts are generated at later stages (17).  Since HIV-1 mRNA in the culture 
supernatant represents virion release, it is considered to be a more accurate measure of the latent 
reservoir (17).  However, T cell activation assays with viral RNA readout also involve a single 
round of stimulation and therefore cannot detect INPs.  Furthermore, qRT-PCR measures of viral 
RNA in these assays may detect defective proviruses that are not capable of productive infection.  
Due to the potential of obtaining both false-negative and false-positive results, these assays cannot 
accurately quantify the latent reservoir (17). 
1.2.2  PCR-based assays   
Unlike the VOA, PCR-based assays will detect both induced and noninduced proviruses and 
therefore overestimate the true size of the latent reservoir, having shown that approximately 
300/106 resting CD4+ T cells contain HIV-1 DNA (56).  Numerous PCR assays have been designed 
for the detection of specific forms of proviral DNA that exist within HIV-infected individuals.  
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Total proviral DNA includes replication-competent and defective proviruses, as well as 
unintegrated forms of HIV-1 DNA (17).  HIV DNA is commonly detected by qPCR using primers 
based on conserved regions of the HIV-1 genome (17).  This method provides quantitation of 
proviral DNA relative to a standard curve rather than an absolute value (73-85).  Droplet digital 
PCR (ddPCR) is a more precise assay for the absolute quantitation of total HIV-1 DNA that is 
based on water-oil emulsion partitioning of DNA into droplets, such that amplification of template 
molecules occurs in each individual droplet (56, 86-88).  Compared to traditional PCR, this method 
permits the measurement of thousands of independent amplification events within a sample.   
As a result of studies suggesting that linear HIV-1 DNA that fails to integrate into the host 
genome is unstable (89, 90), assays measuring the latent reservoir should detect only stably 
integrated proviruses.  PCR assays that can distinguish integrated from extrachromosomal HIV 
DNA have become useful in addressing this issue.  Among these, Alu-PCR has become the most 
common method for selectively amplifying integrated proviruses (91-95).  This assay employs 
primers that target Alu elements, which are short sequences of transposable DNA found in high 
copy numbers within the human genome, and the HIV-1 gag gene (17).  Subsequently, nested RT-
PCR using primers in the HIV-1 LTR is performed (17). Alu-PCR is useful for detection of 
integrated proviral DNA in untreated viremic individuals, in whom most HIV-1 DNA exists in a 
linear, unintegrated form (96).  Disadvantages of Alu-PCR include the inability to detect 
proviruses integrated too far from an Alu sequence to be amplified, and the ability to detect 
defective proviruses.   
Other forms of unintegrated HIV-1 DNA that do not contribute to latency are 1- and 2-
LTR circles.  1-LTR circles are formed as a result of failed integration and subsequent homologous 
recombination between the two LTRs of linear HIV DNA (97), whereas 2-LTR circles result from 
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non-homologous end joining between LTRs (98). Though controversial, 2-LTR circles are 
considered a measure of ongoing viral replication or recent infection, based on the assumption that 
they are labile (75, 99-101).  Both qPCR (75, 102, 103) and ddPCR (56, 88) assays have been 
developed to detect 2-LTR circles in resting CD4+ T cells and PBMC, but 1-LTR circles have 
proved difficult to quantify by PCR-based methods (104-106). 
Due to the fact that ongoing viral replication occurs in HIV-infected individuals on 
suppressive ART (107), much effort has been devoted to the development of more sensitive assays 
to measure residual viremia.  Whereas the limit of detection of most clinical assays is 50 copies of 
HIV-1 RNA/mL plasma, highly sensitive single-copy assays (SCA) capable of detecting as low as 
1 copy/mL plasma (108-110) have recently been developed. The RT-PCR SCA assay uses primers 
based on conserved regions of HIV-1 gag to measure ongoing viral replication originating from 
CD4+ T cells and other cellular reservoirs (45).  A revised version of the SCA employing primers 
for a highly conserved region of integrase in the HIV-1 pol gene and larger volumes of plasma 
reported increased sensitivity compared to the gag SCA (111).  However, the SCA is time-
consuming and has a limited dynamic range due to the fact that HIV-1 RNA levels in most ART-
suppressed individuals are near the limit of detection of the assay (17).  Furthermore, since the 
SCA measures residual plasma viremia but excludes cell-associated proviral DNA, it is not a direct 
measure of the latent HIV reservoir.  In summary, accurate quantification of the latent reservoir is 
unachievable with current culture- and PCR-based assays. 
1.2.3  Single-cell characterization of latent HIV-1    
Shortcomings of standard assays to quantify the latent reservoir have led to the advent of 
techniques that aim to detect latent HIV-1 on a single-cell level.  This highly precise technology 
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combines fluorescence in situ hybridization for HIV-1 gene-specific mRNA (112) and flow 
cytometry staining for HIV Gag protein to allow simultaneous detection of HIV transcription and 
translation products in CD4+ T cells harboring inducible latent provirus (113, 114).   Commercially 
available as PrimeFlow™ (RNAflow) and RNAscope® ISH (RNAscope), these assays employ 
multiple oligomeric probes and branched DNA signal amplification to enhance detection 
sensitivity (113, 114).  This approach has been used to evaluate the efficacy of LRAs in 
reactivating latent HIV-1 in either in vitro models of latency or CD4+ T cells from HIV-infected 
individuals (113, 114).  For example, Baxter et al. used gag and pol probe sets for HIV-1 mRNA 
in combination with flow cytometry staining for phenotypic markers and intracellular Gag to 
identify the transcription- and translation-competent reservoir in latently infected cells from HIV-
infected individuals following treatment with various LRAs (113, 115).  Evaluation of RNAflow 
and RNAscope using LRA stimulation in the J-Lat cell model showed that RNAscope is more 
sensitive and specific, with a lower limit of detection than RNAflow (114).  Next-generation in 
situ hybridization techniques combining detection of viral RNA-positive (vRNA+) (RNAscope) 
and vDNA+ (DNAscope) cells and immunohistochemistry are being used to characterize tissue 
reservoirs of latent HIV and SIV infection (113, 116).  Importantly, this powerful technology 
permits discrimination of infected vDNA+ cells that are actively transcribing HIV mRNA 
(vRNA+) from those that are transcriptionally silent (vRNA-) (117), which has been instrumental 
in demonstrating that ongoing viral replication occurs in anatomical sanctuaries (54, 118). 
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1.3 Therapeutic approaches to HIV-1 latency reversal 
The ‘kick and kill’ (or ‘shock and kill’) approach to controlling HIV-1 involves inducing HIV-1 
latency reversal (LR) during ART to expose infected cells, while creating an arsenal of immune 
effector cells, such as CTL, capable of eliminating these targets (119). Finding an effective means 
to expose and purge the latent reservoir in a nontoxic manner has been elusive and remains a major 
hurdle to this cure approach.  Though pharmacological latency reversal agents (LRAs) have 
achieved limited success in ex vivo studies, in over 15 clinical trials none have been shown to 
reduce the latent reservoir in HIV-1-infected individuals (120-122).  The first HIV eradication 
trials were based on the knowledge that induction of latent provirus is dependent on T cell 
activation (9, 89).  Two human trials utilizing anti-human CD3 (OKT3) in combination with IL-2 
not only failed to produce reductions in the reservoir but also proved toxic to participants, 
prompting discontinuation of the use of global T cell activating agents in subsequent studies (123, 
124).  Summarized in Table 1, current LRAs can be divided into mechanistic classes that include 
epigenetic modifiers, protein kinase C (PKC) agonists, NF-κB agonists, phosphoinisitide-3-kinase 
(PI3K)/Akt pathway inhibitors, T cell receptor (TCR) activators, toll-like receptor (TLR) agonists, 
and various unclassified compounds (125). 
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LRA Class Mechanism(s) of action References
HDACi epigenetic modifiers acetylation of histones 125, 127-132
HMTi epigenetic modifiers demethylation of histones 125, 127, 133-136
DNMTi epigenetic modifiers demethylation of DNA 32, 125, 127, 137
BETi epigenetic modifiers inhibit BRD4 interaction with active P-TEFb; P-TEFb releasing agent 125, 138-144
P-TEFb activators epigenetic modifiers phosphorylation of CDK9 125, 145
HMBA epigenetic modifiers phosphorylation of RNA Pol II; BRD4 activation; chromatin remodeling; P-TEFb releasing agent 138, 146-149
Bryostatin-1 PKC agonists mimic DAG; activate PKC isoforms to initiate downstream NF-κB signaling 115, 125, 126, 159, 164
Prostratin PKC agonists mimic DAG; activate PKC isoforms to initiate downstream NF-κB/AP-1 signaling 125, 126, 150, 154, 155
Ingenols PKC agonists mimic DAG; activate PKC isoforms to initiate downstream NF-κB signaling 125, 126, 167-171
Smac mimetics NF-κB agonists inhibit cIAP1 to prevent degradation of NIK (NF-κB-inducing kinase) 125, 126, 174
Immune checkpoint blockers TCR activators TCR signaling 125, 190
Disulfiram PI3K/Akt pathway depletes PTEN to activate Akt signaling and NF-κB-mediated transcription 125, 126, 129, 178, 179, 181
Benzotriazole PI3K/Akt pathway STAT5 signaling 126, 182-184
Rapamycin PI3K/Akt pathway mTOR inhibitor; disrupts formation of mTORC1 125, 126, 185, 186
TLR7 agonists TLR agonists MyD88-dependent NF-κB and JNK signaling 125, 191-193
TLR9 agonists TLR agonists MyD88-dependent NF-κB and JNK signaling 125, 194
Quinolones unclassified inhibit BRD4 interaction with active P-TEFb; P-TEFb releasing agent 125, 213-215
IL-15 unclassified unknown 125, 212
Galectin-9 unclassified NF-κB, AP-1, NFAT signaling; inhibits expression of repressive chromatin-modifying factors 221
Akt, protein kinase B; AP-1, activator protein 1; BETi, bromodomain and extraterminal bromodomain inhibitors; BRD4, bromodomain-containing protein 4; DAG, diacylglycerol; DNMTi, DNA 
methyltransferase inhibitors; HDACi, histone deacetylase inhibitors; HMBA, hexamethylene bisacetamide; HMTi, histone methyltransferase inhibitors; JNK, c-Jun N-terminal kinase; mTOR,
mammalian target of rapamycin; mTORC1, mTOR complex 1; MyD88, myeloid differentiation primary respnse 88; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor κ light chain-
enhancer of activated B cells; PKC, protein kinase C; P-TEFb, positive transcription elongation factor b; PTEN, phosphatase and tensin homolog; STAT5, signal transducer and activator of
transcription 5. 
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1.3.1  Epigenetic modifiers   
Epigenetic modifiers include histone deacetylase inhibitors (HDACi), histone methyltransferase 
inhibitors (HMTi), DNA methyltransferase inhibitors (DNMTi), bromodomain and extraterminal 
(BET) bromodomain inhibitors (BETi), positive transcription elongation factor b (P-TEFb) 
activators, and HMBA (hexamethylene bisacetamide) (125, 126).  All of these compounds operate 
at various levels of transcriptional control to mediate changes in chromatin structure that permit 
proviral reactivation.  
HDACi facilitate acetylation of histones, an activating epigenetic mark characteristic of 
open chromatin (127).  Within this class of LRAs, HDACi have been most extensively studied, 
and clinical trials of vorinostat, panobinostat, and romidepsin have all demonstrated HIV 
reactivation in vivo (128-132).  However, none of these agents impacted levels of HIV-1 DNA.  
HMTi and DNMTi interfere with methylation of histones and DNA, respectively, which are 
repressive epigenetic marks of closed chromatin (125, 127).  Several inhibitors of histone 
methyltransferases (HMT) associated with proviral silencing including SUV39H1, G9a, and 
EZH2, have facilitated HIV-1 latency reversal in model cell lines and in resting CD4+ T cells ex 
vivo (133-136).  DNMTi that have been investigated in clinical trials for various forms of cancer 
are currently being explored for their antilatency potential.  Specifically, decitabine (Aza-CdR) 
and its analog azacitidine (Vidaza®) have demonstrated HIV-1 reactivation in various in vitro 
models of latency (32, 137).  Classified as P-TEFb releasing agents, BETi block the BET 
bromodomain interaction of bromodomain-containing protein 4 (BRD4) with acetylated histones 
that facilitates P-TEFb recruitment to the HIV-1 LTR in the absence of Tat (138), thereby 
promoting Tat-mediated recruitment of P-TEFb to the viral promoter (139-141).  BETi also 
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mediate P-TEFb release from the repressive 7SK small nuclear ribonuleoprotein (snRNP) complex 
(139).  In addition, BETi compounds including JQ1, I-BET, I-BET151, and MS417 have been 
shown to induce HIV LR in both in vitro models of latency as well as in primary cells from ART-
suppressed individuals ex vivo (139, 140, 142-144).   
LRAs that directly activate P-TEFb are also under investigation.  During HIV transcription, 
the switch from initiation to elongation occurs upon successful recruitment of P-TEFb by Tat to 
the TAR element within the nascent HIV transcript, which is mediated partly by phosphorylation 
of negative factors and hyperphosphorylation of the C-terminal domain of RNA polymerase II 
(127).  For example, the P-TEFb activator Amt87 facilitates this switch by phosphorylating the 
cyclin-dependent kinase 9 (Cdk9) subunit of P-TEFb, thereby releasing P-TEFb from the 7SK 
snRNP and inducing assembly of the Tat-super elongation complex (SEC) at the HIV-1 promoter 
(145).  Finally, the P-TEFb releasing agent (138) HMBA induces Tat-independent proviral 
transcription through Cdk9-dependent phosphorylation of the C-terminal domain of RNA Pol II 
and subsequent recruitment of Cdk9 by Sp1 to the HIV-1 LTR (146, 147).  HMBA has also been 
shown to activate the P-TEFb recruitment factor BRD4 (148, 149) and to mediate chromatin 
remodeling at nucleosome 1 (Nuc-1) near the HIV transcription start site (TSS), independent of 
histone acetylation or methylation (146).  
1.3.2  PKC agonists 
PKC agonists induce HIV LR through activation of NF-κB signaling by intracellular PKC isoforms 
(126).  These compounds mimic the second messenger diacyglycerol (DAG), which activates PKC 
enzymes to initiate downstream signaling, leading to NF-κB binding at the LTR and viral 
transcription.  PKC agonists can be divided into three chemical families, including phorbol esters, 
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macrocyclic lactones, and diterpenes (126).  Phorbol esters under investigation include phorbol 
12-myristate 13-acetate (PMA), prostratin, and 12-deoxyphorbol 13-phenylacetate (DPP), all of 
which operate through NF-κB and Ap-1 signaling pathways to reactivate latent provirus (150).  
Despite its effectiveness as a strong inducer of T cell activation and HIV transcription, PMA is not 
a candidate for clinical LR trials due to its oncogenic properties (151-153).  However, both 
prostratin and DPP have demonstrated potential as T cell activators and LRAs in latently infected 
primary cells ex vivo (154, 155). 
Originally isolated from the marine sponge Bugula neritina, the macrocyclic lactone 
bryostatin-1 has been implemented extensively in clinical oncology trials for its anti-neoplastic 
properties (156-158).  Although the potent PKC agonist was shown to achieve T cell activation 
comparable to that induced by PHA/Il-2 stimulation in vitro and ex vivo (120, 159), its use in 
cancer clinical trials resulted in serious adverse events (160-163).  Furthermore, in a phase I HIV-
1 clinical trial, tolerable but conservative drug dosing of bryostatin-1 prevented it from reaching 
detectable systemic concentrations associated with PKC activation and from reactivating latent 
HIV-1 reservoirs (164).   
The third family of PKC agonists, the diterpenes, includes ingenol compounds first isolated 
from the Euphorbia family of plants (126).  In addition to their numerous medicinal properties 
(165), ingenols were discovered to inhibit HIV-1 replication by blocking viral adsorption through 
downregulation of CD4 and viral coreceptors CCR5 and CXCR4 (166, 167).  Synthetic ingenol 
compounds have shown promise as LRAs in various models of in vitro latency (167, 168) and in 
nonhuman primates (169).  The FDA-approved actinic keratosis drug ingenol-3 angelate 
(PEP0005) (170) exhibited synergism with the BETi/P-TEFb agonist JQ1 in reactivating latent 
HIV in primary CD4+ T cells from ART-suppressed individuals (171).  Furthermore, 
18 
coadministration of Ingenol B and vorinostat to rhesus macaques resulted in increased SIV viral 
load in both the periphery and the CNS (169).  However, the combined LR activity of Ingenol B 
and vorinostat in this study was also accompanied by systemic and CNS inflammation.  In 
concordance with these results, subsequent in vitro data suggest that the PKC agonists prostratin 
and bryostatin-1 may promote blood-brain barrier disruption and transmigration of 
proinflammatory leukocytes into the CNS (172). 
1.3.3  NF-κB agonists 
Among NF-κB agonists, second mitochondrial-derived activator of caspases (Smac) mimetics are 
a class of LRAs that act via the non-canonical NF-κB pathway to mediate proviral transcription 
(126).  Smac is known as a mediator of apoptosome formation and activator of the caspase cascade 
in mitochondrial apoptosis pathway (125, 173).  In HIV latency reversal, Smac mimetics inhibit 
the cellular inhibitor of apoptosis protein 1 (cIAP1) that ubiquitinates NF-κB-inducing kinase 
(NIK).  NIK is required for the phosphorylation of IκB kinase alpha (IKKα), which in turn 
processes p100 into p52, resulting in the formation of RelB/p52 heteodimers that can translocate 
to the nucleus to induce NF-κB-dependent transcription (126).  Thus, Smac mimetics prevent 
degradation of NIK, which culminates in NF-κB-dependent transcription and coincident induction 
of integrated provirus (174). 
1.3.4  PI3K/Akt pathway inhibitors 
Compounds that target the phosphoinisitide-3-kinase (PI3K)/Akt pathway are also being 
investigated for their potential as LRAs.  In vivo, activation of PI3K/Akt signaling promotes cell 
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survival by blocking steps in the apoptosis pathway (175-177).  Three mechanistically distinct 
classes of LRA candidates have demonstrated PI3K/Akt-dependent reactivation of latent HIV-1.   
An FDA-approved drug used for the treatment of alcoholism, the acetaldehyde 
dehydrogenase inhibitor disulfiram was first shown to induce proviral transcription in a primary 
cell model of latency (178).  Disulfiram reactivates NF-κB-dependent viral gene expression by 
depleting the phosphatase and tensin homolog (PTEN), a tumor suppressor that negatively 
regulates intracellular levels of phosphatidylinositol-3, 4, 5-triphosphate (PIP3) and the Akt 
signaling pathway (179).  Based on the in vitro finding that disulfiram could induce LR in the 
absence of global T cell activation, the drug has been tested in human clinical trials, which 
demonstrated slight increases in viral RNA (180, 181) that were accompanied by a 14% decrease 
in reservoir size (181).   
Benzotriazole derivatives reactivate latent HIV through a mechanism that involves γc-
cytokine-dependent phosphorylation of the transcription factor STAT5 (signal transducer and 
activator of transcription 5) (182).  Sustained phosphorylation of STAT5 is required for its 
activation and translocation to cognate binding sites within the viral promoter (183).  Covalent 
addition of the protein SUMO2/3 (Small Ubiquitin-like Modifier 2/3) to STAT5 prevents 
phosphorylation and nuclear import of STAT5.  Benzotriazoles inhibit this interaction to permit 
STAT5-mediated HIV transcription (182).  Importantly, benzotriazoles have been reported to 
reactivate latent HIV-1 in vitro and ex vivo without toxicity or global T cell activation (184).   
Finally, the mTOR (mammalian target of rapamycin) inhibitor rapamycin has been 
investigated not as an LRA itself, but for its ability to mitigate the cytokine-associated toxicity and 
proliferative effects of potent T cell stimulating agents employed in latency reversal strategies 
(185).  Rapamycin is an immunosuppressive compound that exerts its effects on the PI3K/Akt 
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pathway downstream of IL-2 signaling (186) by disrupting formation of mTOR complex 1 
(mTORC1), which is a regulator of cellular metabolism and activation.  Martin et al. determined 
that rapamycin downregulated proinflammatory cytokine release and cellular proliferation in anti-
CD3/CD28-activated resting CD4+ T cells from ART-suppressed individuals but did not inhibit 
HIV-1 reactivation (185).  Of relevance to ‘shock and kill’ approaches for targeting the latent 
reservoir, rapamycin did not impair CTL effector function (185). 
1.3.5  TCR activators 
The TCR-activating class of LRAs includes immune checkpoint (IC) inhibitors (ICIs).  It has been 
hypothesized that ICIs used for reversal of exhaustion in HIV-specific T cells displaying ICs could 
potentially de-repress HIV latency in CD4+ T cells coexpressing these markers (187).  Two 
previous cases of HIV-infected cancer patients treated with either Programmed Cell Death-1 (PD-
1) or Cytotoxic T Lymphocyte-associated Protein-4 (CTLA-4) monoclonal antibodies reported no 
effects on latent HIV reservoirs (188, 189).  However, to date one HIV-infected individual treated 
with anti-PD-1 (nivolumab) for non-small-cell lung cancer experienced increases in plasma viral 
load and decreases in cell-associated HIV DNA that were accompanied by increases in CD8+ T 
cell function and decreased CD8+ T cell exhaustion, suggesting that nivolumab induced synergistic 
‘shock and kill’ effects in this patient (190). 
1.3.6  TLR agonists 
The LR potential of TLR7 agonists has been investigated in several ex vivo and in vivo studies 
(191-193).  The compound GS-9620 induced extracellular HIV-1 RNA in PBMCs of virally 
21 
suppressed individuals, increased cytolytic activity of HIV-specific CD8+ T cells, and enhanced 
killing of infected cells mediated by the HIV envelope-specific broadly neutralizing antibody 
(bNAb) PGT121 (191).  In these studies, both latency reversal and T cell activation were dependent 
on type I IFNs produced through TLR7 stimulation of pDC.  Of note, GS-9620 was also able to 
induce polyfunctional T cell cytokine responses independent of antigen specificity in PBMC from 
HIV-naïve individuals in response to CEFT peptides.   
More recently, TLR7 agonists have been employed in vivo to target the latent reservoir.  
Therapeutic vaccination with Ad26/MVA (recombinant adenovirus serotype 26 prime/modified 
vaccinia Ankara boost) expressing SIVsmE543 gag-pol-env and stimulation with the TLR7 agonist 
GS-986 increased the breadth of SIV-specific CTL responses, decreased levels of lymph node and 
peripheral blood SIV DNA, and delayed viral rebound following ART interruption in SIVmac251-
infected rhesus macaques (192).  These effects were attributed to the combination of therapeutic 
vaccination and innate immune stimulation and could not be achieved by TLR7 stimulation alone.  
In a study of SHIV-SF162P3-infected rhesus macaques, administration of the HIV-1 Env-specific 
bNAb PGT121 in combination with TLR7 agonist GS-9620 during ART delayed viral rebound 
upon ART discontinuation (193).  Adoptive transfer of lymph node mononuclear cells from 
monkeys that did not rebound during the study period did not transfer infection to SHIV-naïve 
monkeys.  Furthermore, viral loads remained undetectable in monkeys that did not rebound 
following CD8 depletion.  Importantly, this study highlights the potential of a bNAb-TLR7 agonist 
combination to target the viral reservoir, even in the absence of therapeutic levels of bNAbs 
following discontinuation of ART (193).  Now termed vesatolimod, GS-9620 has advanced to 
Phase 1b clinical trials.  To be completed in February 2019, clinical trial NCT02858401 
(http://www.clinical trials.gov NCT02858401) is a placebo-controlled dose-escalation study 
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investigating the safety and tolerability of vesatolimod in HIV-1-infected, ART-suppressed 
participants and its effect on changes in plasma HIV-1 RNA.  Another current placebo-controlled 
trial of vesatolimid (http://www.clinical trials.gov NCT03060447) is investigating the safety and 
efficacy of a 10-dose regimen in ART-treated HIV-1-infected controllers on ART and during 
analytic treatment interruption (ATI).     
The efficacy of TLR9 agonist MGN1703 as an innate immunity enhancer and LRA was 
evaluated in a single-arm, open-label study (http://www.clinical trials.gov NCT02443935) of HIV-
1-infected, ART-suppressed individuals who were administered the drug subcutaneously twice 
weekly for 4 weeks (194).  Study outcome measures included assessment of pDC, NK, and T cell 
activation; plasma HIV-1 RNA and cytokine levels, and interferon-stimulated gene (ISG) 
expression.  Activation of pDC, increases in plasma IFN-2α, upregulation of ISG transcription in 
CD4+ T cells, and increased proportions of activated NK and CD8+ T cells resulted from 
MGN1703 treatment.  Increases in plasma HIV-1 RNA > 1500 copies/mL were also detected in 6 
of 15 participants.  However, MGN1703 dosing did not impact reservoir size, as measured by 
levels of total and integrated HIV-1 DNA (194).  The upcoming clinical trial TITAN 
(http://www.clinical trials.gov NCT03837756) will evaluate the safety and efficacy of TLR9 
agonist lefitolimod in combination with the bNAb 3BNC117/10-1074 in HIV-1-infected 
individuals on ART and during ATI, and its impact on HIV-1 reservoir reduction. 
In earlier studies, TLR5 and TLR1/2 agonists were explored as potential LRAs.  The TLR5 
agonist flagellin was shown to induce NF-κB-dependent transcription of HIV RNA from healthy 
donor resting central memory CD4+ T cells (TCM) that were in vitro infected with recombinant 
luciferase-encoding HIV-1 particles (195).  Since TCM constitute the major latent HIV-1 reservoir 
in vivo, and gut-associated lymphoid tissue (GALT) contains the largest pool of TCM, this study 
23 
supports previous findings that microbial translocation and low-level proliferation of TCM in the 
gut contribute to chronic immune activation and virus dissemination in HIV-1-infected individuals 
(82, 195, 196).  However, flagellin could not reactivate latent provirus in resting CD4+ T cells from 
aviremic individuals (195). 
The TLR1/2 agonist Pam3CSK4 reactivated latent HIV-1 in an in vitro latency model 
incorporating healthy donor naïve CD4+ T cells that were infected with defective virus and cultured 
to induce a TCM phenotype (197, 198), and in TCM of virally suppressed HIV-infected individuals 
(199).   Interestingly, virus transcription was mediated by cooperative NF-κB, NFAT, and AP-1 
signaling, in the absence of T cell activation and proliferation.  Since Pam3CSK4 induced latent 
provirus selectively, it could be an attractive therapeutic target in latency reversal strategies that 
aim to prevent global T cell activation (199). 
1.3.7  Unclassified LRAs 
LRAs with unclassified mechanisms of action that are under study include the cytokine IL-15, 
quinoline compounds, and galectin-9 (125).  IL-15 is a cytokine produced by activated dendritic 
cells and macrophages that activates NK and CD8+ T cells to kill virus-infected cells (200-202).  
IL-15 is presented in trans to NK and CD8+ T cells as part of a membrane-bound IL-15:IL-15Rα 
complex (201, 203), but can also be secreted as a monomer.  IL-15/IL-15Rα heterodimers cleaved 
from DC and macrophage membranes have greater biological activity and a longer serum half-life 
than IL-15 monomers (204, 205), and thus complexes of recombinant IL-15 and soluble 
recombinant IL-15Rα have been synthesized to create IL-15 ‘superagonists’ that recapitulate the 
in vivo heterodimer functionality (206).  Il-15 superagonists have been shown to promote in vivo 
NK and CD8+ T cell effector responses to cancer (207-210) and to HIV-1 infection in humanized 
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mice (211).   In a recent study, both IL-15 and the IL-15 superagonist ALT-803 induced LR activity 
in a primary CD4+ T cell model of HIV latency (212), and ALT-803 also enhanced CTL killing of 
HIV-infected cells ex vivo (212).  ALT-803 is currently in several human clinical cancer trials for 
solid and hematological malignancies (NCT01946789, NCT01885897, NCT02099539), and dose 
escalation studies are being performed to assess whether ALT-803 can be tolerated at doses 
determined to be safe in cynomologous macaques (212). 
Quinolines were first identified as potential LRAs for their ability to reactivate latent HIV 
in Bcl-2-transduced primary CD4+ T cells in the absence of undesirable nonspecific T cell 
activation (213).   The quinolone compound MMQO (8-methoxy-methylquinolin) was discovered 
by small molecule library screening for agents capable of reacting HIV-1 in the latently infected 
J-Lat cell line (214).  MMQO activates transcription of latent provirus by inhibiting the BRD4 
protein that competes with Tat for association with the P-TEFb kinase complex (215).  Thus, 
inhibition of BRD4 permits Tat-mediated recruitment of P-TEFb to the HIV mRNA TAR element 
and transcription elongation (127).  In this regard, MMQO may also be classified as a novel BET 
inhibitor whose mechanism of action is the same as that of JQ1.  Utilizing barcoded HIV ensembles 
(B-HIVE) technology, this study also determined that MMQO targets a different subset of HIV-1 
integration sites than those targeted by HDACi or PKC agonists (215). 
The human carbohydrate-binding protein galectin-9 (Gal-9) gained attention for its 
possible role in HIV latency reversal as a result of data demonstrating that it regulates expression 
of the host restriction factor and cell cycle regulator (132, 216) p21 (217-219).  In addition, a recent 
study found that viral transcription in ART-treated HIV-infected individuals is regulated by p21 
(220).  Abdel-Mohsen et al. demonstrated that recombinant Gal-9 (rGal-9) potently reactivated 
latent provirus in vitro in J-Lat cells and ex vivo in CD4+ T cells from virally suppressed HIV-
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infected individuals (221).  The mechanism of rGal-9-mediated LR involved signaling through N-
linked oligosaccharides and O-linked hexasaccharides on the T cell surface, which also induced 
expression of the proviral transcription initiation factors NF-κB, AP-1, and NFAT, and the host 
antiviral restriction factor APOBEC3G (apolipoprotein B mRNA editing enzyme catalytic subunit 
3G) (221).  Conversely, rGal-induced signaling inhibited gene expression of several repressive 
chromatin-modifying factors, including HDAC-1, -2, and -3; EZH2, SUV39H1, DNMT1, BAF, 
and BCL11B (221).  Interestingly, plasma levels of soluble Gal-9 in HIV-infected individuals on 
ART correlated with cell-associated HIV RNA and with levels and binding avidity of circulating 
HIV-specific antibodies, which may suggest that Gal-9 mediates LR in vivo (221).    
1.3.8  LRA combination therapy  
Both ex vivo studies and clinical trials have demonstrated that no single pharmacological LRA in 
current use has been able to reactivate a significant proportion of the latent HIV-1 reservoir (152, 
222).  In addition, it is unclear whether multiple doses of a single LRA improve the efficacy of 
latency reversal, as in vivo studies of single and multiple dose administration of the HDACi 
vorinostat reported greater increases in cell-associated HIV RNA after a single administration to 
participants (128, 223).  In an effort to address these issues, cure strategies are employing 
combinations of LRAs from different mechanistic classes, with the hypothesis that 
pharmacological synergy could facilitate increased viral reactivation with a single dose, while 
mitigating potential deleterious side effects of multiple dose regimens (126).  
An extensive study by Laird et al. investigating the efficacy of LRA combinations in 
patient samples ex vivo determined that PKC agonists in combination with either HDACi or the 
BETi JQ1 were most effective at inducing HIV transcription compared to maximum reactivation 
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by PMA/ionomycin (152).  In agreement with these findings, the PKC agonist/BETi LRA 
combinations bryostatin-1 + JQ1 and Ingenol-B + JQ1 synergized to achieve levels of ex vivo viral 
reactivation comparable to positive control stimulation using anti-CD3/CD28 antibodies in another 
recent study (138).  Furthermore, several HMTi in combination with either JQ1 (224), the PKC 
agonist prostratin, or HDACi such as vorinostat (225), have enhanced proviral reactivation in both 
T cell lines and in resting CD4+ T cells ex vivo (224, 225).  Among atypical LRAs, galectin-9 
potently reversed latency in patient cells ex vivo when combined with JQ1 (221).  These and 
numerous other studies demonstrate that synergy between various LRA mechanistic classes is 
achievable, albeit not easily interpreted in different in vitro and ex vivo systems.  It is also important 
to note that in vitro latency models routinely used to interrogate LRA function do not accurately 
recapitulate LR in vivo, and results of these studies must be interpreted with caution (132, 226, 
227).  As such, in vitro functional studies of LRA activity should be validated using relevant animal 
models and clinical studies to be considered physiologically relevant.  Furthermore, some 
pharmacological LRAs, specifically histone deacetylase inhibitors and PKC modulators, inhibit 
the killing of HIV-1-infected cells by negatively impacting antigen-specific CD8+ T cell effector 
responses (discussed below) (159, 226), which is an important consideration in the design of both 
single and combination LRA approaches.  All of these findings necessitate an effective eradication 
strategy capable of reversing latency without global T cell activation (228) or impairment of 
cytolytic effector function. 
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1.4 Alternative approaches to the ‘kick and kill’ of latent HIV-1  
Due to the major hurdles encountered thus far in the ‘kick and kill’ approach to HIV-1 eradication, 
numerous alternative strategies for combating latent HIV infection are gaining attention.  For 
example, compounds shown to induce apoptosis in cancer chemotherapy are currently being 
explored for their potential to eliminate latently HIV-infected cells, either alone or in combination 
with LRAs (125).  Of interest, the Bcl-2 (B cell lymphoma-2) protein family includes pro- and 
anti-apoptotic molecules and sensors of apoptotic stimuli that regulate apoptosis through the 
mitochondrial, or intrinsic, pathway (125, 229, 230).  Cellular stress, DNA damage, and radiation 
are among triggers of apoptosis via this route, leading to mitochondrial permeabilization, 
apoptosome formation, and activation of the caspase cascade (173, 231).  Apoptosis can also be 
negatively regulated by inhibitor of apoptosis (IAP) family members that prevent caspase 
activation (229).  Bcl-2 antagonists have been investigated for use in cancer immunotherapies due 
to their ability to block the anti-apoptotic function of Bcl-2 family proteins, which are 
overexpressed in various cancers (232-234).  Levels of anti-apoptotic Bcl-2 are also elevated in 
resting CD4+ T cells upon reactivation of HIV latency (233).  Bcl-2 antagonists permit HIV 
protease-dependent apoptosis in reactivated, latently infected resting CD4+ T cells by preventing 
Bcl-2-mediated sequestration of the HIV protease-derived, pro-apoptotic Casp8p41 protein (233).  
Licensed for the treatment of chronic lymphocytic leukemia, the compound Venetoclax has been 
shown to reduce the frequency of latently HIV-infected, anti-CD3/CD28-reactivated T cells from 
ART-suppressed individuals ex vivo (233, 235).  In addition, the potential utility of Venetoclax in 
reducing HIV-1 reservoir establishment was demonstrated in vitro through selective elimination 
of infected primary T cells during productive infection (236).  However, the efficacy of Bcl-2 
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inhibitors in combination with LRAs that do not induce maximum T cell activation is unknown 
(125).    
The PI3K pathway promotes cell survival through inhibitory phosphorylation of pro-
apoptotic molecules or transcription factors by the serine/threonine kinase second messenger Akt 
(175-177).  Since expression of HIV Nef and Tat proteins early in the virus life cycle activates 
PI3K/Akt signaling to prevent premature apoptosis of infected cells, inhibition of key effectors in 
the PI3K pathway is being explored as a potential strategy for promoting apoptosis-induced 
elimination of these cells (237-239).  The Akt inhibitors Edelfosine, Perifosine, and Miltefosine 
were shown to inhibit HIV-induced Akt activation in vitro, resulting in death of infected 
macrophages (239), which constitute a long-lived viral reservoir in vivo.  The use of the PI3K 
inhibitor CUDC-907 in combination with LRAs has been proposed as a ‘kick and kill’ strategy for 
its dual abilities to inhibit class I PI3K isoforms and HDAC class I and II enzymes (125, 240, 241).  
However, the selection of LRAs in such combination approaches warrants careful consideration, 
as some have demonstrated opposing effects on PI3K inhibitor activity (125).  For example, the 
LRA disulfiram depletes a negative regulator (PTEN) of the PI3K/Akt pathway, promoting NF-
κB-mediated proviral transcription and survival of infected cells (178, 242).  Furthermore, the 
LRA activities of HDAC inhibitor vorinostat and PI3Kα isoform agonist 55704 also activate 
PI3K/Akt signaling (243).  In fact, clinical trials of vorinostat (128) and disulfiram (180, 244) 
revealed no reduction in HIV DNA in virally suppressed participants.  Conversely, use of PI3K 
inhibitors in combined strategies could negatively impact latency reversal through inhibition of 
transcription factors necessary for HIV-1 replication (125).    
Another potential target of HIV-1 ‘kill’ interventions is the second mitochondrial-derived 
activator of caspases (Smac) that mediates apoptosome formation and subsequent activation of the 
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caspase cascade when released into the cytosol (173, 231).  Smac mimetics promote apoptosis by 
competitively binding and inactivating inhibitory apoptosis proteins (IAPs), such as the X-linked 
inhibitor of apoptosis (XIAP) that inhibits caspases 3, 7, and 9 (125).  The Smac mimetic Birinipant 
and the XIAP antagonists GDC-0152 and Embelin produced dose-dependent increases in selective 
apoptosis of HIV-infected primary resting CD4+ T cells without the addition of LRAs (245).  
Importantly, this study implies that selective elimination of latently infected cells may be achieved 
in the absence of reactivation.  In another study, pretreatment with the Smac mimetic AEG40730 
sensitized monocyte-derived macrophages to Vpr-induced apoptosis (246). 
Finally, inducers of the viral RNA-sensing pattern recognition receptor (PRR) RIG-I 
(retinoic acid-inducible gene I) are another focus of apoptosis-mediated HIV-1 cure approaches.  
Detection of HIV RNA by RIG-I induces antiviral immune responses and apoptosis of infected 
cells (247).  As retinoic acid (RA) can induce RIG-I expression and HIV transcription through 
activation of the transcription factor p300 acetyltransferase (19), treatment with RA mimetics 
could simultaneously reactivate latent provirus and promote RIG-I-mediated apoptosis of infected 
cells.  In vitro, the RA derivative Acitretin was shown to induce HIV transcription and selective 
apoptosis of latently infected CD4+ T cells of ART-suppressed individuals, as well as decreases in 
HIV DNA (19).  In combination with Acitretin, vorinostat enhanced selective elimination of HIV-
infected cells compared to uninfected cells in latently infected T cell lines (19).  However, these 
findings could not be reproduced in a subsequent study by Garcia-Vidal et al. (248).  Nevertheless, 
an attractive feature of LRA/apoptosis-inducing combination strategies is lack of dependence on 
effective CTL responses or complications arising from immune escape (125). 
Besides pro-apoptotic compounds, the clustered regularly interspaced short palindromic 
repeat (CRISPR)-Cas system that functions as an adaptive immune system in bacteria and archaea 
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by detecting and eliminating foreign nucleic acids of invading pathogens (249-251) has also been 
harnessed for use in strategies to target the latent HIV-1 reservoir (252).  Employing the Cas9 
endonuclease of Streptococcus pyogenes, the modified CRISPR-Cas9 system cleaves double-
stranded DNA (dsDNA) in a sequence-specific manner, mediated by a guide RNA that directs 
Cas9 to a complementary sequence in the target DNA (252).  Compared to the nonspecific, global 
TCR-activating effects of most pharmacological LRAs, this approach is highly desirable.  
However, although this tool was widely explored in earlier genome editing HIV cure strategies to 
either excise proviral DNA from latently infected cells (253-255) or to render host cells less 
susceptible to HIV infection through knockout or knockdown of viral coreceptor expression (256-
260), possible introduction of deleterious mutations resulting from error-prone NHEJ DNA repair 
prompted development of therapies with fewer off-target effects (252, 261).  Furthermore, 
mutations preventing gRNA binding to target DNA sequences and use of gRNAs targeting poorly 
conserved proviral sequences can lead to the development of Cas9/gRNA-resistant escape variants 
(252).  As a result, further modification of the CRISPR-Cas9 system through mutation of the Cas9 
endonuclease catalytic domains has been explored for use in ‘shock and kill’ strategies to activate 
transcription of integrated HIV-1 (252, 261).  The resulting ‘deactivated’ or ‘death’ Cas9 (dCas9) 
variant lacks dsDNA cleaving activity while retaining gRNA-mediated sequence-specific DNA 
binding affinity (252).  Fusion of the dCas9 protein to a viral or cellular transcription factor-derived 
activation domain (AD) facilitates recruitment of transcription-activating and chromatin 
remodeling factors upon gRNA-directed targeting of the dCas9-AD fusion protein to specific 
promoter or enhancer sequences within the HIV-1 LTR (252).  While this strategy circumvents 
host cell DNA damage, as with the original CRISPR-Cas9 construct, concerns remain regarding 
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potential off-target genetic effects and the ability to deliver the technology efficiently to all latently 
infected or HIV-susceptible cells in vivo (252).  
1.5 Permanent suppression of HIV-1 reactivation as a functional cure strategy   
Due to evidence that some level of ongoing viral replication occurs in the lymphoid tissues of 
ART-suppressed individuals (50), even more recently the focus has shifted from ‘kick and kill’ 
strategies to target the latent HIV-1 reservoir to strategies aimed at permanently repressing viral 
reactivation.  Termed ’block and lock’ (262), this cure approach targets viral proteins that are 
strong regulators of HIV-1 transcription.  A particularly attractive candidate is the viral 
transactivator of transcription (Tat) protein and its interaction with the HIV RNA transactivation 
reponse element (TAR), whose inhibition has been the goal of several in vitro and ex vivo studies 
(262-267).  During HIV-1 transcription, the switch from initiation to elongation occurs upon 
successful recruitment of positive transcription elongation factor b (P-TEFb) by Tat to the TAR 
element within nascent transcripts at the HIV-1 promoter (127).  Thus, antagonists of Tat itself or 
of the Tat/TAR interaction have been explored as inducers of permanent HIV-1 latency that is 
refractory to viral reactivation by standard LRAs (27).  Among compounds being investigated as 
Tat inhibitors, didehydro-Cortstatin A (dCA), an analog of the natural steroid Cortistatin A, 
prevents transactivation of the HIV-1 promoter by competitively binding to the TAR-binding 
domain of Tat (265, 266).  Both in vitro and ex vivo, dCA treatment was shown to induce an almost 
permanent state of proviral latency that was resistant to disruption upon ART discontinuation or 
by potent stimulation with the PKC agonist prostratin (265, 266).  Kessing et al. further 
demonstrated that dCA-mediated epigenetic silencing of the HIV-1 promoter resulted from 
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increased nucleosome occupancy at Nucleosome-1, and that dCA could not only suppress viral 
rebound after treatment interruption but also reduce tissue HIV-1 RNA levels in ART-suppressed 
bone marrow-liver-thymus (BLT) mice (262).  Triptolide, another Tat inhibitor that has been 
historically used to treat rheumatoid arthritis, is currently the subject of a Phase III clinical trial 
(NCT02219672) investigating its impact on reservoir seeding during acute HIV-1 infection (27).  
Triptolide was shown to inhibit HIV-1 transcription by promoting proteasomal degradation of Tat 
(268).   One distinct advantage of Tat-focused ‘block and lock’ strategies is that Tat has no cellular 
homologs (27), and therefore concerns regarding nonspecific or off-target effects that could result 
from ‘shock and kill’ strategies implementing pharmacological LRAs or the CRISPR-dCas9 
system, respectively (261), could be circumvented. 
Among potential targets of non-Tat-based latency strengthening therapies is heat shock 
protein 90 (HSP90), which is required for NF-κB-dependent HIV-1 reactivation under 
hyperthermic conditions (27, 269).  Inhibitors of HSP90 were shown to block HIV-1 reactivation 
in J-Lat cells, supporting the role of HSP90 in latency reversal (269).  Furthermore, the telomerase-
derived peptide vaccine GV1001, currently in Phase II clinical cancer trials, suppressed HIV-1 
reactivation by PMA in vitro, but its antiviral activity was completely abrogated by HSP90-
neutralizing antibody (270).  Another recent therapeutic strategy exploits the interaction between 
HIV-1 integrase (IN) and the host cofactor lens epithelium-derived growth factor (LEDGF)/p75, 
to retarget viral integration to transcriptionally silent regions of the genome, rendering the reservoir 
refractory to reactivation by various LRAs (271).  This class of integration inhibitors, termed 
LEDGINs, bind the LEDGF/p75 binding pocket of IN (272, 273), thereby depleting LEDGF/p75 
and redirecting lentiviral integration out of transcription units (274).  Vranckx et al. demonstrated 
that LEDGIN treatment decreased the reactivation potential of latent provirus by LRAs including 
33 
TNF-α, suberoylanilide hydroxamic acid (SAHA), prostratin, and phorbol 12-myristate 13-acetate 
(PMA), in various cell lines and in primary CD4+ T cells (271).   
Inhibition of the HIV-1 Rev protein has also been explored as a mechanism to establish 
deep latency for its role in regulating the export of unspliced and singly spliced viral mRNAs from 
the host cell nucleus (126).  The Rev inhibitor ABX464 was shown to suppress viral replication in 
vitro and in HIV-1-infected humanized mice, leading to extended control of viral rebound in 
ABX464-treated mice after removal of ART (275).  Finally, in addition to its potential as an LRA, 
the aforementioned CRISPR-dCas9 system could also be modified for use as a latency 
strengthening agent (LSA) (261).  Rather than reactivating HIV-1 gene expression in a sequence-
specific manner using dCas9 activators, gRNA-directed binding of the dCas9 protein to 
transcription factor binding sites within the HIV LTR can be used to inhibit proviral transcription 
(252).  Binding of the dCas9/gRNA complex to NF-κB and Sp1 sites was shown to prevent binding 
of these transcription factors and reduced subsequent LTR-driven gene expression (276, 277).  In 
addition, dCas9 repressors can be designed by fusion of dCas9 to repressor domain proteins to 
facilitate more active repression of transcription than would be accomplished by interference with 
transcription factor binding alone (252).  Among natural and artificially engineered repressor 
domains, the Kruppel-associated box (KRAB)-containing zinc finger proteins were shown to 
inhibit HIV LTR activity in numerous studies through targeting of the TAR element (278-284).  
Importantly, when combined with ART, ‘latency strengthening’ (261) functional cure approaches 
would limit chronic immune activation and inflammation associated with residual viremia (102, 
285), as well as reservoir expansion facilitated by chronic inflammation (285).    
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1.6 Challenges for the kill phase of HIV-1 cure 
Numerous clinical trials of pharmacological LRAs including vorinostat, disulfiram, bryoststin-1, 
panobinostat, and romidepsin, have shown that although proviral reactivation is achievable in vivo, 
elimination of reactivated cells is minimal to nonexistent (128-130, 132, 164, 180, 286).  These 
results highlight problems inherent with the use of current LRAs in ‘shock and kill’ strategies to 
target the latent reservoir by demonstrating that the ‘kill’ does not necessarily follow latency 
reversal, regardless of sufficient expression of viral RNA or antigens by infected cells (122, 287).  
A successful anti-HIV memory response requires CTL recognition of cells expressing peptide 
antigen derived from replication-competent proviruses following latency reversal (288).  HIV-1 
epitopes presented by infected cells in the context of MHC class I are recognized by HIV-specific 
resting memory CTL that have become activated upon recall of HIV-1 antigen.  Activated CTL 
subsequently kill infected target cells through release of perforin and granzymes.  However, the 
challenges associated with effective killing of latently infected cells are multifactorial.   
First, CTL recognition of HIV-1 epitopes is hampered by escape mutations that are selected 
early in infection due to heightened immune pressure (289-292) and continue to contribute to the 
latent reservoir until the initiation of ART (288).  Proviruses with escape mutations to 
immunodominant CTL epitopes comprise a significant portion of the latent reservoir in individuals 
who initiate ART in the chronic stage of HIV-1 infection (293).  Thus, successful CTL-based HIV 
eradication strategies must target subdominant viral epitopes for which escape mutations have not 
accumulated.  Alternatively, selective induction of new HIV-specific CTL through priming of 
naïve CD8+ T cells can achieve recognition of persistent HIV in individuals on ART, without 
targeting existing, dysfunctional memory T cells (294). 
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A second challenge of the ‘kill’ phase is the excess of defective proviruses that occupy the 
latent reservoir in vivo.  These defective proviruses (HIV-1def) can result from hypermutations, 
large internal deletions, packaging signal deletions, major splice donor (MSD) mutations, or 
inactivating point mutations (57, 59, 295) and significantly outnumber cells harboring replication-
competent proviruses.  As a result of intact LTR promoter function, integration into actively 
transcribed genes, and lack of promoter methylation, some HIV-1def can be transcribed, translated, 
and recognized by HIV-specific CTL (57, 58, 295).  Specifically, cells containing HIV-1def with 
hypermutations or packaging signal/MSD mutations are decoy targets for CTLs and act to divert 
CTL-mediated elimination of the true latent reservoir (295).  Pollack et al. demonstrated the 
phenomenon of ‘cold target’ inhibition using CD4+ T cells transfected with reconstructed defective 
proviruses derived from HIV-infected individuals on ART, cocultured with autologous CTL 
clones specific for Gag and Nef epitopes (295).  In another recent study, autologous CTL clones 
eliminated HIV-infected cells that had undergone IL-15-mediated latency reversal, demonstrating 
decreases in total HIV-1 DNA but not in inducible, replication-competent proviruses (296).  It has 
been postulated that preferential targeting of HIV-1def  may be a function of their ability to present 
antigen to CTLs more efficiently as a result of a defect in Nef and the inability to downregulate 
MHC class I (295).  However, the role of HIV-1def  in vivo, where the effector-to-target ratio will 
likely differ depending on anatomical site and not reflect the defined ratio used in ex vivo culture, 
warrants investigation (295).  Of note, a study in SIV-infected macaques receiving therapeutic 
vaccination revealed a > 2 log decrease in HIV DNA that was accompanied by a 1 log decrease in 
intact proviruses, pointing to elimination of cells harboring defective proviruses (192).  Evidence 
that clonal expansion of cells containing both defective and replication-competent HIV-1 shapes 
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the pool of latently infected cells in individuals on long-term ART (25, 37, 38, 41, 63) poses an 
additional challenge to targeting only those proviruses that are a barrier to an HIV cure. 
Additional complications of ‘shock and kill’ approaches that utilize pharmacological LRAs 
for the ‘shock’ are the negative impact of some of these compounds on CTL effector function.  
Jones et al. demonstrated that in vitro exposure of CD8+ T cells to the HDAC inhibitors (HDACi) 
vorinostat (SAHA), romidepsin, and panobinostat impaired IFN-γ production, and that even 
transient exposure to romidepsin or panobinostat induced selective death of activated T cells (226).  
HDACi impaired proliferation of HIV-specific CD8+ T cells, as well as elimination of HIV-
infected or peptide-pulsed target cells (226).  Romidepsin exhibited the greatest inhibitory activity 
at all doses tested (226).  These findings were subsequently confirmed by Clutton et al., who 
determined that in comparison to HDACi, PKC modulators induced stronger T cell activation, 
proliferation, and nonspecific cytokine production (159).  With the exception of vorinostat, all 
LRAs tested reduced antigen-specific CD8+ T cell functions, the extent and timing of which varied 
between LRAs (159).  LRA toxicities were a factor of both duration of exposure to drug and culture 
period, with bryosastin-1 being the most toxic (159).  Though effective as LRAs in combination, 
bryostatin-1 and romidepsin (152) were shown to inhibit elimination of reactivated autologous 
CD4+ T cells by primary HIV-1-specific CD8+ T cells in both chronic progressors and elite 
controllers (297).  In this study, bryostatin-1 or bryostatin-1/romidepsin combination treatment 
caused increases in CD8+ T cell death, and bryostatin-1 treatment alone induced increases in 
expression of exhaustion markers PD-1, TIM-3, 2B4, and CD160 (297).  Walker-Sperling and 
colleagues also confirmed downregulation of CD3 expression on CD8+ T cells subject to 
bryostatin-1, prostratin, or bryostatin-1/romidepsin combination treatment, which could interfere 
with the ability of CTLs to recognize cognate antigen (297).  Finally, the immunosuppressive 
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effects of LRAs extend beyond CTL function, as HDACi have been shown to reduce degranulation 
and killing capacity of NK cells (298). 
CTL exhaustion is another critical consideration in the design of effective kill phase 
strategies.  T cell exhaustion can occur in the settings of chronic viral infections or cancer, as a 
result of persistent immune activation and antigen exposure (288, 299-302).  Among defects in 
CTL function that arise during chronic HIV-1 infection, exhaustion cannot be fully reversed with 
ART (303).  Exhaustion in antigen-specific T cells involves a gradual loss of effector function, 
accompanied by decreased proliferative capacity (304).  Compared to terminally differentiated or 
memory CD8+ T cells, exhausted CD8+ T cells are characterized by decreased cytokine production 
and cell surface expression of inhibitory receptors including PD-1, TIM-3, CTLA4, CD160, LAG-
3, and TIGIT (304-309).  Increases in inhibitory receptor expression serve as immune checkpoints 
(ICs) to limit excess T cell activation during a normal immune response and are downregulated 
upon its resolution (307, 310).  Conversely, sustained expression of inhibitory receptors results 
from persistent antigen exposure, leading to an exhausted phenotype.  Even in the context of 
suppressive ART, in which exposure to HIV antigen is limited, it may not be possible to completely 
restore CTL functionality (288).  This is illustrated by high levels of PD-1 and TIGIT expression 
by both follicular and nonfollicular CD8+ T cells in the lymph nodes of HIV-infected individuals 
(311).  However, immune checkpoint blockade combination therapies approved for use in cancer 
immunotherapy have been shown to reverse exhaustion to varying degrees in virus-specific T cells 
(301, 309, 312, 313).  In a recent study, in vitro blockade of the PD-1/PD-L1 axis in follicular and 
nonfollicular lymph node cells restored HIV-1-specific CD8+ T cell function (311).  Importantly, 
correlations between HIV DNA content in memory CD4+ T cells and expression of PD-1, TIGIT, 
and LAG-3 inhibitory receptors have been documented, suggesting a potential role for these ICs 
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in latency establishment (288, 314, 315).  Information gleaned from these studies could be used to 
boost CTL function of lymph node CXCR5-expressing CD8+ T cells and subsequent targeting of 
the latent reservoir within this compartment (288).  A phase I clinical trial of the anti-PD-L1 
antibody BMS-936559 has produced encouraging results, demonstrating a trend toward enhanced 
Gag-specific CD8+ T cell responses in virally suppressed HIV-1-infected participants (316). 
Finally, one of the greatest challenges of targeting the HIV reservoir for CTL-mediated 
elimination is the spatial separation of target and effector cells in anatomical ‘sanctuaries’ (54) that 
serve as a persistent source of latent provirus.  For example, the CD4+ T follicular helper (TFH) and 
T follicular regulatory (TFR) cell subsets within B cell follicles of lymph nodes are more permissive 
to HIV-1 infection than extrafollicular (EF) subsets ex vivo (317-319) and comprise a major 
portion of the latent reservoir during both chronic SIV and HIV infection (320-323).  CTLs are 
excluded from the B cell follicle because they usually lack the follicular homing receptor CXCR5, 
which is not expressed until late in untreated infection (320).  As a result, target cells within the 
follicle are protected from CTL-mediated cytolysis, whereas viral replication in EF zones is 
efficiently controlled (324).  Indeed, ongoing SIV replication within TFH cells of elite controller 
macaques has been attributed to CTL exclusion from B cell follicles, as depletion of SIV-specific 
CD8+ T cells resulted in increased viral replication in non-TFH CD4+ T cells (54).  In support of 
this finding, CD8 depletion in chronically infected rhesus macaques revealed greater increases in 
SIV RNA+ non-TFH cells relative to TFH cells (325).  In addition to limitations of trafficking, some 
reports suggest that follicular CXCR5+CCR7- CD8+ T cells are less cytolytic than CXCR5-CCR7- 
extrafollicular CTL.  In SIV-infected rhesus macaques, follicular CTL frequently colocalized with 
regulatory T cells (TREG) or expressed the exhaustion marker PD-1 (325).  In human tonsils, 
approximately 90% of follicular CD8+ T cells were characterized as CD44hiCXCR5hi follicular 
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TREG expressing IL-10, TGF-β, TIM-3, and low levels of perforin (326).  This CD44hiCXCR5hi 
subset was also shown to suppress TFH-mediated immune responses to HIV infection ex vivo (326).  
However, other studies document that the rare CXCR5+CD8+ T cell population exhibits increased 
cytolytic potential compared to CXCR5-CD8+ T cells.  For example, peripheral blood 
CXCR5+CD8+ T cells from HIV-infected individuals were characterized by higher levels of IFN-
γ production and a less exhausted phenotype than EF CD8+ T cells in a recent study by He et al. 
and inversely correlated with viral load (327).  Furthermore, lymph node CXCR5+CD8+ T cells 
expressed higher levels of perforin compared to the CXCR5-CD8+ subset (327).  Petrovas et al. 
confirmed this finding, but reported increased PD-1 expression and decreased polyfunctional 
cytokine responses in follicular CD8+ T cells (311).  In summary, the mechanisms governing CTL 
migration to and cytolytic activity within B cell follicles are poorly understood, and novel 
strategies to address barriers to CTL targeting of this compartment are being explored.  Among 
these, temporary disruption of the B cell follicle with depleting antibodies (anti-CD20/rituximab), 
blockade of T and B cell interactions using anti-CD40L, and therapeutic vaccination with 
engineered CTL or chimeric antigen receptor T cells expressing CXCR5 have been proposed (54, 
324).  Transduction of CTL with CXCR5 to facilitate B cell follicle homing has been demonstrated 
in rhesus macaques (328).  In addition, in vitro stimulation with TGF-β was able to induce CXCR5 
expression in CXCR5-CD8+ T cells from chronically SIV-infected rhesus macaques (329).  
Besides their latency reversal properties, recombinant IL-15 and the IL-15 superagonist ALT-803 
have both been shown to augment HIV-specific CTL responses and are thus being explored as 
enhancers of follicular CTL function (212, 324).  Another promising approach involves the use of 
bispecific antibodies targeting CD3 and HIV gp120 that have the dual capacity to act as LRAs and 
to facilitate ADCC in gp120-expressing cells (330).  Interestingly, the recently developed 
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CD3/VRC07 antibody was also shown to induce killing of HIV-infected cells by follicular CTL 
ex vivo (311).  Although this remains to be tested in vivo, lymph node-homing CXCR5+CD8+ T 
cells could be transduced to produce these antibodies in order to facilitate killing of latently 
infected cells within the B cell follicle (324). 
1.7 Dendritic cell programming for immunotherapy 
Derived from the bone marrow, dendritic cells serve as bridge between the innate and adaptive 
immune systems due to their dual capacity to respond to pathogen- and danger-associated signals 
during acute inflammatory responses and to process and present antigens for the priming of naïve 
T cells (331).  Although the principal human DC subsets in vivo consist of three main types (331), 
models of DC ontogeny have undergone numerous revisions since the discovery of DC by Ralph 
Steinman and Zanvil Cohn (332, 333) greater than 40 years ago.  Due to recent experimental data 
supporting modification of the classical model of hematopoesis that regulates DC lineage, it is now 
accepted that DC originate not from a population of mutipotent progenitor cells but from 
progenitors that follow predestined developmental pathways determined by lineage priming (334-
337).   
DC are further classified based on  differential expression of transcription factors such as 
interferon regulatory factors 4 and 8, which distinguish plasmacytoid DC (pDC, IRF4+IRF8+), 
myeloid/conventional DC1 (cDC1, IRF4-IRF8+), and myeloid/conventional DC2 (cDC2, 
IRF4+IRF8-) (331, 338-341).  Characterized by surface expression of CD123 and CD45RA, pDC 
produce high levels of type I and type III interferons in response to viral infection in the forms of 
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single-stranded RNA and double-stranded DNA detected by endosomal toll-like receptors 7 and 
9, respectively (331, 342, 343).   
Myeloid cDC1 were initially classified as a subset of blood DC expressing high levels of 
CD141 (thrombomodulin) (344, 345) but also reside in numerous lymphoid and nonlymphoid 
tissues (331).  Identification of cDC1 is also based on shared expression of CD13 and CD33 with 
cDC2 and low expression of CD11b, CD11c, and CD172 (331); unique to cDC1 is the receptor 
that recognizes actin exposed during cell necrosis, CLEC9A (346, 347).  Myeloid DC1 have a 
superior capacity to cross-present viral and intracellular antigens in the context of MHC class I for 
activation of CD8+ T cells and induction of T helper type 1 (TH1) and natural killer (NK) cell 
responses (348-351).  Like pDC, cDC1 produce both type I and type III interferons in response to 
pathogen sensing via TLR3 and TLR9 (331, 352-354). 
The predominant human cDC population in blood, as well as lymphoid and nonlymphoid 
tissues, cDC2 are characterized by various surface antigens, including CD1c, CD2, CD172, FcεR1, 
CD11b, CD11c, CD13, and CD33 (331).  Similar to monocytes, cDC2 express an extensive 
repertoire of lectins and pattern recognition receptors that facilitate immune responses to agents as 
diverse as intracellular pathogens, extracellular bacteria, parasites, and fungi (331).  Furthermore, 
cDC2 are capable of inducing TH1, TH2, TH17, and TREG immune responses, due to their ability to 
secrete various pro- and anti-inflammatory mediators (331, 355-357).  Of note, cDC2 are weak 
producers of type III interferons but can be stimulated to produce high levels of IL-12 compared 
to cDC1 (358-361). 
Ex vivo generation and programming of DCs was first implemented in cancer 
immunotherapy to circumvent the dysfunction of endogenous DCs that occurs in cancer patients 
(362-367).  In contrast to traditional vaccines that relied on antigen cross-presentation by patients’ 
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own dysfunctional DCs, this strategy harnessed functional DCs generated outside of the tumor-
associated suppressive environment to induce effective anti-cancer immunity (362-367).  This 
concept was based on the premise that monocyte-derived DC could be imprinted during maturation 
with particular effector functions and homing properties for the induction of tumor-specific CD8+ 
T cells in vivo (368).  The first advantage of this approach is that ex vivo-generated DC can be 
loaded with specific antigens that will promote effective delivery of both antigen (‘signal 1’) and 
costimulation (‘signal 2’) to antigen-specific T cells.  However, the ability of DC to cross-present 
antigen is affected by DC developmental stage and by the combination of factors used in their 
activation and maturation (369-373).  In addition, shortcomings of ‘first generation’ DC vaccines 
highlighted the necessity for DC to express high levels of costimulatory molecules and lymph node 
homing capacity in order to induce effective anti-cancer CTL responses (368, 374-377).  As a 
result, ‘second generation’ DC maturation strategies incorporating PGE2 (378-380) were 
developed to induce fully mature DC with high expression of costimulatory molecules (CD83, 
CD86) and CCR7 (Table 2) (381-385).  Although IL-1β/TNF-α/IL-6/PGE2-matured DC displayed 
enhanced immunogenicity and migratory potential in response to lymph node-secreted 
chemokines CCL19 and CCL21 in healthy individuals (374-376, 381, 382), the negative impact 




Since high IL-12p70 production by DC has been shown to greatly enhance their ability to 
induce antigen-specific TH1 cells and CTL (‘signal 3’) (391-401), subsequent efforts to improve 
the efficacy of DC-based cancer vaccines have focused on employing ‘nonexhausted’ DC, unlike 
those matured in the presence of IL-1β/TNF-α/IL-6/PGE2 (380, 383, 402, 403).  These ‘type 1-
polarized’ DC (DC1) were initially generated in the presence of type I and type II interferons and 
TLR ligands, or IL-18-activated NK or memory CD8+ T cells (383, 387, 404-410).  Both in vitro 
and in mouse models, DC1 induced strong, long-lived tumor-specific CTL responses (368).  
Furthermore, addition of IFN-γ and LPS or a combination of IFN-γ, TNF-α, and IL-1β, to the 
cytokine maturation cocktail reversed maturation-associated DC exhaustion, producing polarized 
DC capable of increased IL-12p70 production in response to interaction with CD40L-expressing 
CD4+ T cells (383, 387, 408, 411).  DC-derived IL-15, IL-23, and IL-27 (Table 2), as well as DC-
expressed intercellular adhesion molecule 1 (ICAM1) have also been identified as TH1 cell-
polarizing factors (409, 412, 413), whereas monocyte chemotactic protein 1 (MCP1, CCL2) and 
Table 2. Immunotherapeutic potential of ex vivo-educated dendritic cells 
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OX40 ligand (OX40L) promote TH2-type T cell responses (414).  DC can also mediate regulatory 
T cell polarization through production of IL-10 and transforming growth factor-β (TGF-β) (415, 
416). 
Subsequent findings revealed that addition of IFN-α and the TLR 3 ligand 
polyinosinic:polycytidylic acid to maturing DC1 enhanced expression of CCR7 and production of 
chemokines (‘signal 4’) that promote interaction of DC1 with naïve, memory, and effector T cells 
(Table 2) (389).  Specifically, inclusion of IFN-α in the maturation of these ‘alpha type 1-polarized’ 
DC (αDC1) augments production of CXCL9, CXCL10, CXCL11, and CCL5 to promote 
interaction of mature DC with CXCR3- and CCR5-expressing CTL, TH1, and NK cells desirable 
for effector responses (384, 389, 417, 418).  Likewise, IFN-α-induced maturation results in 
reduced production of CCL22 by αDC1, thus avoiding attraction of undesirable CCR4-expresssing 
TREG (389).                  
In sum, while DC1 and PGE2-matured DC (DC2) share similarities in antigen presentation, 
maturation status, and lymph node homing capacity, large discrepancies exist in their capacities 
for optimal cytokine production, chemokine expression related to T cell trafficking, and antigen 
transfer (Table 2).  Thus, correct ex vivo programming is critical to the design of DC-based 
immunotherapies in order to achieve the desired cellular mechanisms in vivo.  Ex vivo generation 
of DC allows manipulation of antigenic ‘signal 1’ and costimulatory ‘signal 2’ for optimal 
activation and expansion of both antigen-specific CD4+ and CD8+ T cells (368).  Education of DC 
to further exploit polarizing ‘signal 3’ and homing ‘signal 4’ can selectively drive the desired 
antigen-specific T cell effector mechanisms and trafficking patterns.  Importantly, this targeted 
combination strategy could improve therapeutic outcomes by circumventing logistic issues related 
to route of DC immunization, timely delivery of DC to the lymph nodes to minimize cytokine 
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exhaustion, and the requirement for large doses of DC to increase the chances of lymph node 
homing (374, 375, 384, 402, 403, 419-422).   
1.8 Dual role for dendritic cells in the ‘kick and kill’? 
Historically, DCs have been implemented safely and successfully in clinical trials investigating 
cellular immunity to cancer (423), due to the critical concept of DC programming to achieve 
functional polarization (383, 385, 410).  Several studies have shown that CD40L ‘help’ provided 
by CD4+ T cells is a determining factor in the successful induction of antigen-specific CTL 
responses by DC through release of IL-12p70 (294, 383, 424).  Consequently, the T cell priming 
capacity of DC is dependent upon their maturation and polarization status and responsiveness to 
CD40L signaling (383, 406, 425).  However, the concept of DC polarization has yet to be 
adequately employed in DC-based HIV immunotherapies.      
The gold standard PGE2-matured DC (DC2) previously implemented in HIV clinical trials 
by our group (426) and others (427) are characterized by suboptimal responsiveness to CD40L 
resulting in a diminished capacity to induce primary CTL responses (294, 383), in addition to an 
exhausted cytokine phenotype (383, 385) and production of the TREG-attracting chemokine CCL22 
(389, 428).  Conversely, the type 1-polarized DC (αDC1) that have achieved success in cancer 
immunotherapies are intentionally programmed to be superior drivers of type-1 cellular immune 
responses.  Among their defining traits, αDC1 exhibit superior responsiveness to CD40L, an 
increased capacity for IL-12p70 production (383) and antigen processing (429, 430), chemokine 
secretion promoting desired T cell trafficking (384, 389), and the ability to induce effective 
primary CTL responses (383, 406, 407).  Of note, CD40L-stimulated DC are able to prime HIV-
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specific naïve CD8+ T cells, thereby inducing the de novo CTL responses that are more effective 
than pre-existing memory CTL at killing virus-infected cells in ART-treated individuals during 
chronic infection (294).  Furthermore, CD40L-induced IL-12p70 production is critical in this 
regard, as it ‘licenses’ DC to prime naïve T cells (431).  Importantly, αDC1 are also able to 
‘reticulate’ (385, 432), forming immune networks that facilitate intercellular transfer of antigenic 
information with lymph node-resident DC (433).   
An early DC-based HIV immunization strategy developed by our group implemented 
autologous mature DC pulsed with HLA*A02-restricted HIV-1 Gag, Pol, and Env peptides and 
influenza A matrix protein peptide administered to participants intravenously or subcutaneously 
(426).  Although the peptide-DC vaccine elicited HIV-specific IFN-γ responses at two weeks 
following the second immunization, the DC type used in this trial was functionally skewed towards 
the DC2 phenotype and thus suboptimal for the induction of long-lived, broadly reactive CTL 
responses.  A subsequent study utilizing the same DC type and HIV-1/influenza peptide 
combination demonstrated an increase in the frequency of CD4+CD25hiFOXP3+ TREG cells post-
vaccination that contributed to suppression of Gag-specific CD8+ T cell polyfunctional cytokine 
responses (434).  However, one of the most impressive HIV immunotherapy trials to date utilized 
DC pulsed with inactivated autologous HIV, which resulted in a 1 log10 decrease in HIV RNA 
setpoint and was associated with increased anti-HIV CD8+ T cell IFN-γ responses (427).  However, 
as with many previous DC-based studies, this trial implemented DC generation methods that yield 
IL-12p70-deficient DC incapable of inducing sustained HIV-specific effector responses.  In an 
attempt to address this issue, Argos Therapeutics investigated ex vivo genetic manipulation of DC 
as a strategy to deliver a constitutive CD40L helper signal to the DC in an HIV immunotherapy to 
treat acute and chronic infections (435-437).  Nevertheless, this approach was unsuccessful due to 
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the fact that constitutive CD40L signaling induces a burst of IL-12 production that ultimately 
creates IL-12p70-exhausted DC that are unresponsive to CD4+ TH cell interaction (294).  A novel 
therapy proposed by Guardo et al. combined TRIMIX adjuvant and an HIV T cell immunogen 
(HTI) for in vivo targeting of DCs by intranodal injections (438).  The previously described 
TRIMIX adjuvant consists of three mRNAs encoding CD40L, the costimulatory molecule CD70, 
and constitutively activated TLR4 (439). The HTI vaccine component consists of Gag, Pol, Vif, 
and Nef mRNA fragments chosen on the basis of antigen-specific CD4+ and CD8+ T cell reactivity 
(440).  Monocyte-derived DC electroporated with this preparation were shown to induce T cell 
proliferation and IFN-γ responses in vitro, and intranodal injection of TRIMIX/HTI induced 
antigen-specific CTL responses in mice (438).  In addition, human lymph node explants treated 
with TRIMIX/HTI activated DCs and induced proinflammatory mediator production.  However, 
the IL-12-producing capacity of the mRNA/DC-based formulation was not investigated in this 
study, therefore providing no information regarding its potential to induce broadly reactive CTL 
required for the long-term control of viremia in the absence of ART (441). 
Interestingly, results of a recent phase I/II clinical trial linked the administration of a DC-
based HIV vaccine designed to induce CTL responses with increased residual viremia in ART-
suppressed individuals following analytic treatment interruption (442).  Comprised of DC loaded 
with HIV-1-infected apoptotic cells, this vaccine induced T cell activation, cytolysis of infected 
cells, and polyfunctional HIV-specific CD8+ T cell cytokine responses a in a subset of participants.  
Although the vaccine did not prevent viral rebound during treatment interruption, the incidental 
findings suggest that the DC-based therapeutic acted as a LRA.  However, that study was also not 
designed to specifically address the use of the DC therapeutic as an LRA, and a number of 
important questions remain, including the roles that DC polarization and antigen presentation 
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could have in the noted phenomenon, and the underlying mechanisms involved.  Overall, although 
DC-based HIV-1 immunotherapies have proven to be safe and well tolerated, they have achieved 
a success rate of only 38% according to meta-analyses (443).  
Although dendritic cells (DC) have been used in HIV-1 clinical trials for their capacity to 
induce antigen-specific T cell responses (426, 427, 444, 445), their HIV-1 LRA potential has been 
underexplored. Historically, most DC-based strategies aimed at the ‘kick’ of latent HIV have 
employed monocyte-derived immature DC (iDC) and DC matured by exposure to bacterial 
antigens (446-448).  Among these studies, several have purported that DC-mediated LR could be 
induced by DC-T cell contact in the absence of antigen presentation and/or mediated by DC-
secreted soluble factors.  For example, van der Sluis et al. reported that interaction of monocyte-
derived dendritic cells (MDDC) with actively proliferating primary T cells resulted in secretion of 
unidentified components by DC to induce latent provirus (446).  However, in this study iDC were 
cultured with T cells that had been preactivated using either PHA or anti-CD3/CD28 beads.  These 
treatments have been shown to reverse HIV-1 latency (72, 151, 222, 449, 450) and thus, it is 
difficult to dissect whether coculture with DC in this study impacted LR, since preactivation of the 
T cells alone could have induced proviral transcription.  It has also been reported that HIV 
replication can be induced by stimulation of T cell surface molecules by antigen-presenting cells 
expressing costimulatory molecules such as CD40 and other B7 family members (451).  For 
example, in an in vitro model of HIV-TB coinfection, upregulation of HIV-1 replication in alveolar 
macrophages required T cell contact as well as lymphocyte-derived cytokines (451).  In this study, 
lymphocyte-macrophage contact resulted in downregulation of inhibitory CCAAT enhancer 
binding protein β and activation of NF-κB, facilitating proviral transcription through derepression 
of the HIV-1 LTR.   
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In yet another study, CD40L-transduced DC were reported to induce latency reversal in J-
Lat and ACH-2 cell lines, independent of DC-T cell contact and mediated by TNF-α (452).  
Similarly, MDDC matured by AIDS-associated pathogens were shown to reactivate latent HIV in 
Jurkat T cells through secretion of TNF-α (448).  Although the incorporation of antigen in DC-
mediated LR has been underexplored, Marini et al. successfully utilized iDC loaded with SEB 
superantigen for reactivation of HIV-1 in in vitro–infected CD4+ T cells (447).  Finally, one recent 
study investigating the latency activation potential of various DC subsets demonstrated that tissue-
resident and blood-derived myeloid DC reactivated virus in vitro from latently infected effector T 
cells with different efficiencies (453).  Nevertheless, none of these DC therapeutics was designed 
with the dual purpose of creating sufficient HIV-1 antigen exposure for successful CTL targeting 
of the cellular reservoir.   
In sum, the quality of DC implemented in HIV-1 immunotherapy trials to date is 
suboptimal to type-1 polarized DC.  I hypothesize that under optimal conditions, a DC-based 
therapeutic strategy can be designed to safely facilitate both the ‘kick’ and ‘kill’ of the latent HIV-
1 reservoir (Figure 1).   I will show that clinically applicable, type 1-polarized, monocyte-derived 
DC (MDC1) are uniquely capable of both activating HIV-1 transcription in latently infected CD4+ 
T cells harboring replication-competent virus and inducing broad HIV-1-specific CTL responses 
that can effectively target the exposed infected cells.  To promote strong HIV-1-specific CTL 
responses, these antigen-presenting MDC1 are deliberately programmed to subsequently release 
high amounts of the critical CTL-inducing cytokine IL-12p70 upon interaction with the CD4+ T 
helper cell factor CD40L (385).  This is achieved using a combination of factors, including IFN-
α, IFN-γ, and the TLR3 agonist poly (I:C), that are designed to mimic maturation events expected 
to occur as a result of DC crosstalk with responding IFN-α-producing pDC and IFN-γ-producing 
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NK cells during the initial phase of a successful antiviral immune response (383, 407).  MDC1 
have already been successfully implemented in clinical oncology trials (368, 396, 429, 454-456) 
due to their superior capacity to drive long-lived CTL responses from naïve T cell precursors (457, 
458) and have recently been approved for use in phase I HIV clinical trials.  I predict that the 
strategic inclusion of heterologous virus-associated antigens, designed to encourage such CD4+ T 
cell ‘helper’ activity through MHC class II presentation, will also facilitate MDC1-mediated LR, 
thus offering a safe and directed means to immunologically expose and target the latent reservoir 









Figure 1. Proposed model of DC-mediated 'kick and kill' 
DC can induce antigen-specific CD8+ and CD4+ T cell responses through presentation of antigenic peptides in the 
context of (1) MHC class-I and (2) MHC class-II molecules, respectively (signal 1) , along with costimulatory factors 
including CD80 and CD86 (not shown, signal 2). Responding CD4+ T cells subsequently provide DC with the 
feedback hyperactivating ‘helper’ signal CD40L (3), necessary for DC release of IL-12p70 (4), which then promotes 
expansion and differentiation of CD8+ antigen-specific effector CTL (5). If the antigen-responsive CD4+ T cells harbor 
latent HIV-1 (6), their activation can result in HIV latency reversal (7), with HIV-1 proteins being transcribed and 
expressed as surface antigen (8). As a result, these exposed infected cells become targets for CTL. We hypothesize 
that MHC-class II presentation of CMV antigen will facilitate CD4+ T cell ‘help’ for CTL induction, while exposing 
CD4+ T cells harboring latent HIV-1.   
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2.0 SPECIFIC AIMS 
2.1 AIM 1.1 
Determine the impact of DC polarization status of antigen-presenting DC on the ability to 
induce HIV-1 latency reversal. 
Hypothesis: If properly programmed, DCs will effectively induce HIV-1 latency reversal.  In Aim 
1.1, I will investigate the ability of differentially matured, monocyte-derived  DC to induce ex vivo 
transcription of latent provirus in autologous CD4+ T cells of virally suppressed individuals.  I 
hypothesize that type 1-polarized, monocyte-derived DC (MDC1) will have a superior capacity to 
induce HIV-1 latency reversal compared to PGE2-polarized, monocyte-derived DC (PGE2-DC).  
Also referred to as αDC1 (383), MDC1 possess several characteristics that make them desirable 
therapeutic vaccine candidates.  Among these, the combination of fully mature status, expression 
of high levels of costimulatory molecules, enhanced lymph node migratory potential, and 
increased IL-12p70 production compared to the ‘gold standard’ PGE2-DC, has not been achieved 
by any DC-based vaccines (383).  In addition, several cytokines produced by DCs, including IL-2 
(459-462), IL-6, IL-7 (463, 464), and TNF-α, have been shown to be potent inducers of latency 
reversal in resting CD4+ T cells of ART-treated individuals (465).   DC-secreted IL-2 has also been 
reported to augment CD40/CD40L interaction (466), as well as serve as a possible ‘signal 3’ for T 
cells (462).  Importantly, IL-2 produced by DCs has been detected in the immune synapse between 
T cells and DCs loaded with cognate antigen (467).  As such, I further hypothesize that DC LRA 
activity will require antigen-driven interaction with CD4+ T cells. 
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2.1.1  Aim 1.1a 
Assess the impact of DC polarization and the requirement for antigen in the DC-mediated ‘kick’.  
2.1.2  Aim 1.1b 
Utilize DC to generate outgrowth of autologous virus to be utilized as antigen for induction and 
assessment of HIV-specific CTL responses, as well as target cells for the assessment of CTL killing 
capacity (Aim 3).  
2.1.3  Aim 1.1c 
Determine if bidirectional signaling through CD40L impacts DC-mediated latency reversal. 
 
2.2 AIM 1.2 
Determine the impact of DC polarization status on the ability to induce HIV-1-specific CTL. 
Hypothesis: If optimally programmed, DCs will induce HIV-1-specific CTL.  Mailliard et al. first 
demonstrated the efficacy of type 1-polarized DC as anticancer vaccines due to their expression of 
functional characteristics critical for induction of long-lived antigen-specific CTL (383).  In 
addition, a recent study determined that novel HIV-1-specfic CTL responses could be selectively 
induced from naïve CD8+ T cells of chonic HIV-infected individuals on suppressive cART by 
priming with autologous virus-loaded type 1-polarized DC (294).  This study also reported that 
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HIV-specific memory CD8+ T cell responses were dysfunctional, resulting in IFN-γ secretion but 
suboptimal effector function (294).  However, the type 1-polarized and PGE2-matured DC types 
have never been directly compared for their ability to prime HIV-specific CTL responses.  As a 
proof of concept, in Aim 1.2 I will utilize autologous CD8+ T cells of HLA-A2+ HIV-naïve 
individuals to investigate the efficacy of differentially polarized MDC1 and PGE2-DC to induce 
HIV-1-specific CTL.  
2.2.1  Aim 1.2a 
Assess the impact of DC polarization on CTL priming capacity.  
2.2.2  Aim 1.2b 
To determine whether CD40L ‘help’ during priming impacts the quality of HIV-1-specific CTL 
responses.  The DC type with higher CTL priming capacity (as determined in Aim 1.2a) will be 
implemented in this aim.    
2.3 AIM 2 
Utilize common viral antigens to facilitate DC unveiling of the latent HIV-1 reservoir within 
CD4+ T cells having antigen specificity to these viruses. 
Hypothesis: Inclusion of viral (CMV, Influenza, HIV) heterologous MHC Class II helper antigens 
will promote interaction of DC with CD40L+ T helper (TH) cells and facilitate exposure of the 
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latent reservoir hidden within these CD4 compartments for immune elimination.  For a DC-based 
LRA to be clinically applicable, antigen other than SEB will be required to facilitate DC-mediated 
activation of latently infected CD4+ T cells.  However, it is unclear whether an antigen-specific 
association with the HIV-1 cellular reservoir exists.  Elucidating which antigen(s) to use would 
allow for a more directed DC-based targeting of antigen-specific CD4+ T cells harboring the virus, 
rather than a global T cell activation approach.  I propose that inclusion of the aforementioned 
common viral antigens as a component of our DC-based therapeutic will promote interaction with 
CD40L-expressing CD4+ TH cells, for the dual purpose of providing immune ‘help’ for DC-
mediated induction of HIV-1-specific CTL responses and facilitating DC-mediated exposure of 
viral antigen-specific CD4+ T cells harboring latent HIV, to simulate a clinically relevant method 
of HIV-1 latency reversal.  The DC type determined to be most effective at mediating both the 
‘kick’ and the ‘kill’ in Aim 1 will be implemented in this aim. 
2.3.1  Aim 2a 
Assess the efficacy of clinically relevant, common viral antigens in facilitating DC-mediated 
latency reversal.  
2.3.2  Aim 2b 
Utilize common viral antigens for DC-mediated generation of autologous target cells to be utilized 
for evaluation of CTL killing capacity (Aim 3).  
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2.4 AIM 3 
Determine the efficacy of MDC1-mediated latency reversal in enhancing susceptibility of the 
HIV-1 reservoir to immune targeting. 
Hypothesis: An optimal DC-mediated latency reversal strategy will create sufficient HIV-1 antigen 
exposure for successful targeting of the reservoir by autologous CTL.   We have recently shown 
that MDC1 are effective inducers of HIV-1 specific CTL, the effector cell type associated with 
early control of HIV infection (468).  However, for CTL to ‘kill’ requires proper surface antigen 
expression on target cells.  Based on the efficacy of MDC1 in inducing HIV-specific CTL 
responses, I will utilize our MDC1-based priming model (294, 383, 418) to generate CTL 
biosensors for use in determining if our DC-based LRA approach exposes the HIV-1 reservoir for 
susceptibility to CTL ‘kill’.  I propose that proviral antigen presented by latently infected CD4+ T 
cells will be recognized by MDC1-primed autologous CTL, resulting in targeted killing of these 
cells.  Furthermore, I will demonstrate that our MDC1-based approach can also facilitate specific 
immune elimination of those cells harboring replication-competent provirus.  
2.4.1  Aim 3a 
Evaluate effector function of MDC1-primed autologous CTL.  
2.4.2  Aim 3b 
Demonstrate HIV-specific killing of DC-induced target cells generated in Aims 1b and 2b by 
MDC1-primed autologous CTL in short-term cytotoxicity assays.    
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2.4.3  Aim 3c 
Demonstrate suppression of viral outgrowth by MDC1-primed autologous CTL in long-term 
cytotoxicity assays.  
2.4.4  Aim 3d 
Assess the ability of MDC1-primed autologous CTL generated in Aim 3a to eliminate latently 




3.0 MATERIALS AND METHODS 
3.1 Study participants 
HIV-1-infected ART-treated participants of the Pittsburgh clinical site of the Multicenter AIDS 
Cohort Study (MACS) were selected for this research.  These participants were documented as 
having begun ART with a median virally controlled treatment duration of 12.3 years (range 1.7 – 
20.8 years; Table 3).  Whole blood products from HIV-1-negative blood donors were purchased 
from the Central Blood Bank of Pittsburgh.  Written informed consent was obtained from 
participants prior to inclusion in the study.  The University of Pittsburgh Institutional Review 






Table 3. Characteristics of study participants 
Participant Time to Time on Viral load* CD4+ T cell count*
ID Age (years) treatment (years) suppressive ART (years) ART regimen* (copies/mL) (cells/mm3)
1 65 0.5 1.7 TUM < 20 1191
2 67 6.0 20.8 EFV + CBV < 20 702
3 77 0 13.2 RTV + RTVB < 20 1007
4 56 1.7 10.5 ATP < 20 973
5 58 5.3 17.8 ABC + CPR 32 476
6 56 0.6 17.5 ATP < 20 779
7 58 5.4 10.7 RTV + RTVB + ATZ + TRU + TUM < 20 936
8 53 6.8 7.9 ATZ + TRU + IST + DCV < 20 351
9 47 8.25 14.2 ABC + LPV + TDF + RTVB < 20 489
10 49 2.7 14.2 ATP < 20 686
11 52 5.25 12.25 EFV + EPZ < 50 721
12 55 2.2 11.8 ATP < 20 434
13 56 6.8 18.25 LAM + RTV + ABC < 20 334
14 55 3.4 3.8 CPR + ODS ud 852
15 51 7.5 11.2 TZV < 20 706
16 71 15.9 12.8 NVP + TRU < 20 535
17 69 6.25 10.0 ATP < 20 263
Asterisk (*), at visit; ud, undetectable. ABC, abacavir; ATP, atripla; ATZ; atazanavir; CBV, combivir; CPR, complera; DCV, descovy; EFV, efavirenz; EPZ,   
epzicom; IST, isentress; LAM, lamivudine; LPV, lopinavir; NVP, nevirapine; ODS, odefsey; RTV, ritonavir; RTVB, ritonavir boosted; TDF, tenofovir disoproxil
fumarate; TRU, truvada; TUM, triumeg; TZV, trizivir.
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3.2 Isolation of monocytes and peripheral blood lymphocytes 
Peripheral blood mononuclear cells (PBMC) obtained from buffy coat or whole blood were 
isolated by standard density gradient separation using Lymphocyte Separation Medium (Corning, 
Manassas, VA).  PBMC were further separated into monocytes and peripheral blood lymphocytes 
(PBL) using a positive selection human CD14 microbeads kit (Miltenyi Biotec, Auburn, CA) 
according to manufacturer’s specifications, and the differentially isolated cells were cryopreserved 
until use. 
3.3 Generation of monocyte-derived DC 
Immature DC were generated from monocytes isolated and cultured for 5 days in Iscove's 
Modified Dulbecco's Media (IMDM) containing 10% fetal bovine serum and 0.5% gentamicin in 
the presence of granulocyte-monocyte colony-stimulating factor (GM-CSF; 1000 IU/mL; Sanofi-
aventis, Bridgewater, NJ) and interleukin-4 (IL-4; 1000 IU/mL; R&D Systems, Minneapolis, MN).  
As previously described (385), mature, high IL-12p70-producing MDC1 and IL-12p70-deficient, 
prostaglandin E2-treated DC (PGE2-DC) were generated by exposure of immature DC at day 5 for 
48 hours to a cocktail of maturation factors containing either interferon (IFN)-α (1000 U/mL; 
Schering Corporation, Kenilworth, NJ), IFN-γ (1000 U/mL; R&D Systems, Minneapolis, MN), 
IL-1β (10 ng/mL; R&D Systems, Minneapolis, MN), tumor necrosis factor (TNF)-α (25 ng/mL; 
R&D Systems, Minneapolis, MN), and polyinosinic:polycytidylic acid (20 ng/mL; Sigma-Aldrich, 
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St. Louis, MO), or IL-1β (10 ng/mL), TNF-α (25 ng/mL), IL-6 (1000 U/mL; R&D Systems, 
Minneapolis, MN), and PGE2 (2 µM; Sigma-Aldrich, St. Louis, MO), respectively. 
3.4 Flow cytometry 
Phenotypic characterization of DC was determined by flow cytometry using cells stained with the 
following antibodies: CD14-PE (clone TÜK4; Miltenyi Biotec, Auburn, CA), CD83-PE (clone 
HB15A; Beckman Coulter, Brea, CA), CD86-PE (clone HA5.2B7; Beckman Coulter, Brea, CA), 
CCR7-FITC (clone 150503; R&D Systems, Minneapolis, MN), OX40L-PE (clone ik-1; BD 
Biosciences, San Jose, CA), Siglec-1/CD169-Alexa Fluor® 488 (clone 7-239; Bio-Rad, Hercules, 
CA), CD209-APC (clone DCN46; BD Biosciences), and HLA-DR-APC-Cy7 (clone L243; 
Biolegend, San Diego, CA).   For surface staining, cells were preincubated with 1X PBS labeling 
buffer containing 2% BSA, 0.1% NaN3, and unfractionated murine IgG (1.0 µg/mL; Sigma-
Aldrich) to block Fc-receptor binding.  CD4+ T cells cocultured with MDC1 were tested weekly 
for the presence of HIV-1 p24 by surface staining for CD3 (APC-H7, clone SK7; BD Biosciences) 
and CD4 (Pacific Blue, clone RPA-T4; BD Biosciences), and intracellular staining with KC57-
FITC antibody (clone FH190-1-1, Beckman Coulter).  Antigen-specific CTL responses were 
assessed by exposing CTL to HIV-1 Gag 9-mer peptides (1 µg/mL) or media alone, and incubating 
with CD107a-FITC (clone H4A3; BD Biosciences) stain mix containing 0.1% monensin (BD 
Golgi Stop™, BD Biosciences) for six hours at 37º C.  Cells were then stained for viability 
(LIVE/DEAD™ Fixable Aqua Dead Cell Stain, Life Technologies), surface expression of CD3 
(APC-H7, clone SK7; BD Biosciences) and CD8 (PerCP-Cy5.5, clone SK1; BD Biosciences), and 
intracellular expression of IFN-γ (IFN-γ-AlexaFluor® 700, clone B27; BD Biosciences). 
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3.5 Functional characterization of differentially matured DC 
DC production of IL-12p70 in response to CD40L-transfected J558 cell (J558-CD40L; a gift from 
Dr. P. Lane, Birmingham, UK) stimulation was determined as previously described (418).  Briefly, 
DC were plated (2.5 x 104 cells/well) in a 96-well flat-bottom plate and stimulated with J558-
CD40L (5 x 104 cells/well) for 24 hours.  Culture supernatants were collected and tested by IL-
12p70 ELISA using the following reagents: Recombinant Human IL-12 Standard (R&D Systems), 
Primary Human IL-12 mAb (Thermo Scientific, Watham, MA), Secondary Human IL-12 mAb, 
Biotin-labeled (Thermo Scientific), HRP-conjugated Streptavidin (Thermo Scientific), TMB 
Substrate Solution (Thermo Scientific), Stop Solution (Thermo Scientific). 
3.6 Induction of HIV-1 LR in CD4+ T cells 
MDC1 were tested for their ability to induce HIV-1 LR by coculture with autologous CD4+ T cells 
in the absence or presence of SEB (Sigma-Aldrich), CMV pp65 (CMVpp65 Recombinant Protein 
or PepTivator® CMV pp65, Miltenyi Biotec), HIV-1 Gag (HIV-1 IIIB PR55 Gag Recombinant 
Protein, NIH AIDS Reagent Program; HIV-1 Gag Recombinant Protein, Sigma-Aldrich; or HIV-
1 Consensus 15-mer Peptides, Sigma-Aldrich), or influenza M1 antigen (Influenza M1 Protein 
(A/California/04/2009) (H1N1), eEnzyme, or PepTivator® Influenza A (H1N1) MP1, Miltenyi 
Biotec).  Briefly, total CD4+ T cells were isolated from cryopreserved PBL derived from HIV-1-
infected MACS participants by negative magnetic bead separation using an EasySep™ Human 
CD4+ T Cell Enrichment Kit (STEMCELL Technologies, Cambridge, MA). CD4+ T cells were 
cocultured with DC in complete IMDM at a ratio of either 1:7 (100,000 DC: 750,000 CD4+ T 
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cells) or 1:10 (100,000:1 x 106) for seven days in 48-well plates.  Total CD4+ T cells from HIV-1-
infected MACS participants were treated with Dynabeads® Human T-Activator CD3/CD28 (Life 
Technologies, Carlsbad, CA) and implemented as a positive control in LR experiments.  The 
cytokines rhIL-2 (Proleukin®, 100 U/mL; Prometheus Laboratories Inc., San Diego, CA) and 
rhIL-7 (1 µg/mL; Miltenyi Biotec, Auburn, CA) were added to the cultures on day 4, and culture 
supernatants were harvested on day 7 for quantitation of HIV-1 RNA.  Where stated, cocultures 
were maintained and the T cells tested for intracellular expression of p24 on days 15-20 by flow 
cytometry.  CD40L blocking antibody (clone MK13A4, 10 µg/mL; Enzo Life Sciences, 
Farmingdale, NY), Leaf™ Purified Mouse IgG1,k isotype antibody (clone MG1-45, 10 µg/mL; 
Biolegend), and efavirenz (300nM; Cayman Chemical, Ann Arbor, MI) were used where shown. 
3.7 Relative Quantification of HIV-1 Gag RNA 
Culture supernatants were ultra-centrifuged (Sorvall Stratos Biofuge) at 45,000 x g for 1 hour at 
4º C to obtain viral pellets from which total RNA was isolated by the RNA-Bee™ method (TEL-
TEST, Inc., Friendwood, TX).  Five microliters of RNA were used for detection of reverse 
transcription using TaqMan® Reverse Transcription Reagents (Life Technologies) according to 
the manufacture’s protocol.  A 20 µL TaqMan® PCR was performed by mixing 5 µL cDNA with 
TaqMan® Universal PCR Master Mix (Thermo Fisher), 500nM each of forward (5'-
CCCATGTTTTCAGCATTATCAGAA-3') and reverse primers (5'-
CCACTGTGTTTAGCATGGTGTTTAA-3'; Integrated DNA Technologies, San Jose, CA), and 
250nM FAM/MGB-labeled probe (5'-FAM-AGCCACCCCACAAGA-MGB-3'; Integrated DNA 
Technologies).  Real-time PCR was performed using the using the ViiA 7 A&B Applied 
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Biosystems instrument (Life Technologies) and the following cycling conditions: 50º C for 2 min, 
95º C for 10 min, 40 cycles of 95º C for 15 sec, and 60º C for 1 min.  Real-time PCR primers and 
probes were based on the HIV-1 pNL4.3 sequence encoding the gag region.  Serially diluted 
pNL4.3 plasmid DNA ranging from 101 to 106 copies applied to each PCR assay served as the 
HIV-1 standard curve.  A no template control was included in each assay to control for PCR cross-
contamination, and each sample was assayed in triplicate.  QuantStudioTM Real-time PCR 
Software (Applied Biosystems, Foster City, CA) was used for PCR data analysis and copy number 
estimation. 
3.8 Generation and characterization of HIV-1-infected CD4+ T cell targets 
Total CD4+ T cells cocultured with antigen-presenting MDC1 and were tested weekly for the 
presence of HIV-1 p24 antigen by intracellular flow cytometry staining with KC57-FITC antibody 
(clone FH190-1-1, Beckman Coulter).  Target cells were pre-screened for p24 expression, and 
cryopreserved for later use as targets in CTL killing assays when they reached at least 10% 
positivity. 
3.9 Induction and expansion of autologous CTL 
Total CD8+ T cells were isolated from cryopreserved PBL by negative magnetic bead separation 
using an EasySep™ Human CD8+ T Cell Enrichment Kit (STEMCELL Technologies).  To induce 
CTL responses as previously described (418), CD8+ T cells were cocultured with autologous 
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differentially matured DC loaded with either HLA-A2-restricted Gag p24 (Gag151–159) 9-mer 
peptide epitopes when using HIV-1-negative blood donors, or Gag p17/p24 overlapping 15-mer 
peptides (1 µg/mL, Sigma-Aldrich) when using HIV-1-infected MACS participants.  The 
cocultures (75,000 DC: 750,000 CD8+ T cells) were treated with or without the addition of either 
25,000 gamma-irradiated (5000 rad) CD40L-transfected J588 cells (J558-CD40L; a gift from Dr. 
P. Lane, Birmingham, UK) (469) or rhCD40L (0.25 µg/mL; Enzo Life Sciences) where stated.  On 
day 5, rhIL-2 (250 U/mL) and rhIL-7 (10 ng/mL) were added to the cultures and every three days 
thereafter.  On day 12, T cell cultures were restimulated with either gamma-irradiated HLA-A2+ 
T2 cells (for induction of primary CTL responses in HLA-A2+ HIV-1-negative donors) or 
differentially matured autologous DC loaded with autologous 9-mer peptides (1 µg/mL) 
corresponding to the viral antigens and DC type used in the initial stimulation.  Antigen-specific 
readout assays were performed between days 20-24 to assess CTL activity. 
3.10 IFN-γ ELISPOT assays 
Autologous CTL (3-5 x 104/well) were tested for reactivity to individual and pooled Gag 9-mer 
peptide antigens (1-10 µg/mL) by ELISPOT assay using anti-human IFN-γ and biotin monoclonal 
antibodies (clones 1-D1K and 7-B6-1; Mabtech, Cincinnati, OH) as previously described (294, 
418).  Recorded values were net responses compared to control wells consisting of CTL exposed 
to assay medium alone.  
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3.11 HIV-1-infected cell killing assays 
CTL effector function was assessed as described previously, with modifications (294).  Briefly, 
MDC1-stimulated total CD8+ T cells were cocultured with autologous DC-induced CD4+ target 
cells at various effector:target (E:T) ratios for 18 hours at 37º C.  Harvested cocultures were stained 
for surface expression of CD8 (PerCP-Cy5.5, clone SK1; BD Biosciences) and intracellular 
expression of HIV-1 p24 (KC57-FITC, clone FH190-1-1; Beckman Coulter).  Effector CD8+ cells 
were excluded from analysis gating, and the percent reduction in infected CD4+ T cells was 
determined at each E:T ratio. For colorimetric cytolytic assays, autologous CD4 cells were stained 
with either CFSE (eBioscience, San Diego, CA) or CellTrace™ Violet (Thermo Fisher) dyes 
following the manufacturer’s protocols. Target cells (CFSE) were then loaded with individual 
peptides at 100 ng/mL in PBS for 60 min at room temperature (RT); excess unbound peptide was 
removed by washing. The CFSE and CellTrace™ Violet dye-labeled cells were mixed in equal 
numbers and coincubated for 18 hours with autologous CTL at various E:T ratios. The antigen-
specific killing of HIV-1 peptide-loaded CD4+ T cells (green) was calculated based on relative 
changes in percentages of the differentially stained target cells remaining, using flow cytometry 
analysis. 
3.12 Viral outgrowth assays 
Total CD8+ T cells were cocultured with autologous p24-expressing CD4+ target cells at various 
E:T ratios as described for the CTL kill assay. Cultures were maintained for eight days, after which 
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culture supernatants were harvested and tested by p24 ELISA (Frederick National Laboratory for 
Cancer Research, Frederick, MD) for CTL-induced viral suppression (418).  
3.13 Quantification of replication-competent HIV-1  
Culture supernatants harvested from LR and viral outgrowth assays were spinoculated onto TZM-
bl cell (NIH AIDS Reagent Program) monolayers (30,000 cells/well) for four hours at 300 g and 
cocultured for 48 hours.  Beta-Glo® reagent (Promega, Madison, WI) was added to PBS-washed 
TZM-bl cell monolayers and incubated for 1 hour at room temperature.  Control supernatants from 
cultured CD4+ T cells of an uninfected donor were treated in parallel.  Chemiluminescence from 
the TZM-bl cells was detected by luminometer as previously described (72).  Sample wells were 
considered positive for the presence of replication-competent virus if the chemiluminescent signal 
exceeded the mean + 2 S.D. of a control sample.  
3.14  Statistical analyses 
Statistical analyses for ELISPOT and ELISA data were calculated using a linear mixed model with 
95% confidence intervals and Wilcoxon matched-pairs signed-ranks test, respectively.  
Differences between MDC1-mediated LR (HIV-1 RNA) were determined by multilevel mixed-
effects tobit regression analyses or Wilcoxon matched-pairs signed-ranks test.  Criteria for 
inclusion in latency reversal experiments were  ≥ 30 copies/mL of viral RNA in the anti-
CD3/CD28 positive control group and ≥ 20 copies/mL of viral RNA in all other experimental 
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groups.  For the purpose of statistical analysis, values < 20 copies/mL of viral RNA were assigned 
a value of 20 copies/mL.  
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4.0 RESULTS 
4.1 MDC1 effectively induce primary HIV-1-specific CTL responses with CD40L ‘help’ 
Successful CTL targeting of the latent HIV-1 reservoir will require recognition of HIV-1-
associated peptide epitopes presented on infected cells upon LR.  Besides latency itself, major 
hurdles for effective CTL elimination of HIV-1 infected cells include issues related to CD8+ T cell 
exhaustion (470), alterations in CTL epitopes, antigen processing, and antigen presentation 
associated with immune escape (471, 472); the establishment of epitope variants that act as partial 
agonists to induce dysfunctional noncytolytic cross-reactive memory CTL responses (294, 418), 
and presentation of target antigen decoys by cells harboring defective virus (295).  Together, these 
points highlight the need to generate highly functional CTL either through induction of de novo 
CD8+ T cell responses, or subdominant memory responses targeting relevant conserved epitopes 
of the reservoir-associated virus. 
We initially compared the use of two clinically applicable, differentially activated DC 
preparations using blood products from HLA-A2+ HIV-1-naïve blood bank donors to test their 
capacity to induce primary HIV-1-specific CTL responses.  As previously described (385), mature 
type 1-polarized monocyte-derived DC (MDC1) and monocyte-derived DC matured in the 
presence of PGE2 (PGE2-DC) were generated for comparison. MDC1 are characterized by their 
mature phenotypic status (Figure 2A) and high capacity to produce IL-12p70 upon subsequent 
stimulation with the CD4+ T cell ‘helper’ signal CD40L, while PGE2-DC are IL-12p70-deficient 




Figure 2. MDC1 are programmed to produce enhanced levels of IL-12p70 upon stimulation with CD40L 
A) Differentially polarized mature DC were analyzed for surface phenotype. Gray histogram peaks of flow cytometry 
plots indicate unstained control samples; peaks shaded in blue represent positive staining for the phenotypic markers 
indicated. Inset numbers refers to MFI. B) Mature DC were plated (2.5 x 104 cells/well) in a 96-well flat-bottom plate 
and cultured in presence or absence of J558-CD40L (5 x 104 cells/well) for 24 hours. Culture supernatants were 
collected and tested by IL-12p70 ELISA. Error bars indicate mean ± S.D.; n = 3. bd = below detection limit of the 
assay (37pg/ml). C) Mature DC were tested for their net IL-12p70-producing capacity above background in response 
to CD40L stimulation. P values were determined by Wilcoxon matched-pairs signed-ranks test. Error bars indicate 










Furthermore, MDC1 express significantly higher levels of sialic acid-binding 
immunoglobulin-like lectin-1 (Siglec-1, CD169) than PGE2-DC (Figure 3A) (unpublished, in 
preparation), which facilitates capture and transfer of HIV-1 virions to CD4+ T cells in a process 
termed trans infection (473, 474).  However, because our proposed MDC1-based immunotherapy 
is intended for in vivo administration during ART, the potential for trans infection of susceptible 
CD4+ T cells is negligible.  Interestingly, the high level of Siglec-1 expression and other adhesion 
molecules may also contribute to the extensive ‘stickiness’ of MDC1, which is evident in the 
morphological differences seen when culturing MDC1 under standard adherent (Figure 3B, left 
panel) vs. low-binding (Figure 3B, right panel) culture conditions (unpublished, in preparation).  
We have found that the use of the low-binding culture surfaces has no impact on the functional 
properties of the MDC1, but this strategy does greatly enhance the yield (Figure 3C) and viability 
(Figure 3D) of these cells when they are cultured in the absence of serum, and therefore may be a 













Figure 3. Impact of Siglec-1 expression on MDC1 morphology 
A) Relative expression of Siglec-1 compared to isotype control staining on MDC1 and PGE2-DC generated from 
healthy donors (n=8). P values were determined by Wilcoxon matched-pairs signed-ranks test. Error bars indicate 
mean ± SEM; ****P<0.0001. B) Bright-field images (original magnification 200X) of MDC1 standard culture (left 
panel) and low-binding culture (right panel), representative of 5 independent experiments from MDC1 of 4 healthy 
donors. C) Relative recovery of MDC1 from standard and low-attachmnet cultures. D) Viability of MDC1 cultured 
under standard and low-attachment conditions. 
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MDC1 also possess the unique ability to ‘reticulate’ (385), forming F-actin-based cellular 
extensions known as tunneling nanotubes (TNTs) in response to the CD4+ TH signal CD40L 
(Figure 4A, left panel) (385).  Blockade of the CD40/CD40L signaling axis abrogates TNT 
formation and significantly decreases IL-12p70 production (Figure 4A, right panel; Figure 4B) 
(Zaccard et al., in submission).  Absent in PGE2-DC (385), TNTs serve as intercellular 
communication networks for the transfer or exchange of ions and electrical signals, proteins, 
organelles, and antigenic information between cells (385, 475-480).  Of significance, TNTs have 







Figure 4. Influence of CD40L blockade on MDC1 morphology and function 
A) MDC1 were cocultured with activated CD4+ T cells in the absence (left panel) or presence (right panel) of CD40L blocking 
antibody for 24 hours prior to imaging. Bright-field images (400X) were enhanced to permit visualization of CD40L-induced 
membrane extensions and nanotube networks. B) Supernatants collected from MDC1 and MDC1/CD4+ T cell cocultures in the 
absence or presence of CD40L blocking antibody were tested for IL-12p70 content by ELISA. P values were determined by 
Wilcoxon matched-pairs signed-ranks test. Error bars indicate mean ± SEM; *P<0.05.  
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MDC1 and PGE2-DC were loaded with HLA-A2-restricted HIV-1 peptide antigen and 
used as in vitro stimulators of autologous CD8+ T cells, in the presence of gamma-irradiated (5000 
rad) CD40L-expressing J558 cells (J558-CD40L), which served as a CD40L+ TH cell surrogate. In 
doing so, we found that MDC1 had a higher CTL priming capacity compared to PGE2-DC (Figure 
5A, B) (424).  Importantly, the effective in vitro induction of long-term CTL responses by MDC1 




Figure 5. MDC1 are superior inducers of HIV-1-specific CTL responses 
A, B) MDC1 and PGE2-DC loaded with HIV-1 Gag151-159 peptide (TLNAWVKVV) were cocultured with autologous 
CD8+ T cells of HLA-A2+ HIV-1-naïve individuals for expansion and characterization of antigen-specific CTLs by 
IFN-γ ELISPOT. Shown are A) IFN-γ responses in the absence and presence of peptide stimulation and B) net values 
above subtracted unstimulated background. P values were calculated using a linear mixed model with 95% confidence 
intervals. Error bars indicate mean ± S.D. **P˂0.01. C) IFN-γ ELISPOT results of CD8+ T cell responses to Gag151-
159 peptide variants induced in 3 different HIV-uninfected donors by autologous antigen-presenting MDC1 in the 







4.2 Antigen presentation by autologous DC drives HIV-1 latency reversal in CD4+ T cells 
Recent evidence linked a DC therapeutic with an increase in residual HIV-1 viremia while the 
study participants were on ART, suggesting that the DC therapeutic acted in some way as an LRA 
(484).   However, the mechanisms involved in this phenomenon are not yet clear, including the 
role that antigen presentation may have played.   Although MDC1 were shown to be strong 
inducers of primary CTL responses (Figure 5), their efficacy as an LRA has not previously been 
explored.   As such, we next compared the capacities of MDC1 and the ‘gold standard’ PGE2-DC 
to induce HIV-1 latency reversal. 
In preliminary experiments, MDC1 and PGE2-DC were generated from ART virally 
suppressed HIV-1-infected MACS participants and cocultured with autologous peripheral blood 
CD4+ T cells in the presence or absence of SEB antigen (Figure 6A).   SEB was used because as a 
superantigen, it can effectively facilitate immune cross-talk between antigen-presenting cells and 
a large percentage (~30%) of SEB-responsive T cells (385).   CD4+ T cells treated with anti-
CD3/CD28 mAb-coated beads were used as a positive LRA control (151).   These experiments 
revealed the inherent difficulty in reactivating latent provirus from CD4+ T cells of virally 
suppressed individuals with variable reservoir sizes and CD4+ T cell counts.  Foremost, the large 
volumes of blood (250 mL) or leukapheresis that were required for the isolation of monocytes and 
peripheral blood lymphocytes needed to perform the experiments were a considerable limitation 
of this study.  Due to the fact that 3 to 5 million CD4+ T cells per experimental condition were 
needed for latency reversal experiments, CD4 recovery from peripheral blood lymphocytes often 
determined the number of experimental conditions investigated and whether experiments could be 
repeated if necessary.  Furthermore, the timing of viral RNA detection post-stimulation also varied 
widely between study participants.  For example, when culture supernatants were tested 
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longitudinally for HIV RNA, inducible provirus did not become detectable at the same time points 
in all participants (Figure 6B) and was noninducible in others.  When comparing MDC1 + SEB 
and PGE2-DC + SEB stimulation and choosing HIV RNA > 100 copies/mL as a criterion, viral 
RNA in culture supernatants became detectable between 5 and 19 days post-stimulation.  Levels 
of inducible provirus varied widely between donors, ranging from 127 to 32,191 copies/mL 
(Figure 6B).   
Comparing the impact of MDC1/Ag vs. PGE2-DC/Ag stimulation over time, we 
determined that although comparable (data not shown), the highest levels of HIV RNA became 
detectable at earlier time points in a greater number of participants with MDC1-mediated LR 
(Figure 6C).  For example, MDC1/Ag stimulation induced the greatest ‘kick’ in eight participants 
at day 5 post-stimulation, whereas PGE2-DC/Ag stimulation produced this effect in only one donor 
at day 5.  In an effort to control for this vast donor variability, we chose to screen participants for 
their ability to respond to maximum anti-CD3/CD28 stimulation (38, 72), and selected only those 
individuals in which LR could be detected by day 7 post-culture for inclusion in the study.  
Accordingly, HIV RNA values obtained only at day 7 post-stimulation were used as a cutoff to 




Figure 6. Timing of DC-mediated HIV-1 latency reversal is highly variable among participants 
A) Model of DC-mediated HIV-1 latency reversal in autologous CD4+ T cells. B) Differentially polarized DC were 
cocultured with autologous CD4+ T cells in the presence or absence of SEB antigen. Cell culture supernatants were
analyzed by qRT-PCR for HIV-1 RNA. Data points indicate day post-stimulation at which HIV RNA reached > 100
copies/mL. C) Differentially polarized DC were cocultured with autologous CD4+ T cells in the presence or absence 
of  antigen. Cell culture supernatants were analyzed by qRT-PCR for HIV-1 RNA. Shown are the days post-
stimulation at which the highest HIV RNA values were detected.
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Using these criteria, qRT-PCR analysis of HIV-1 RNA presence in day 7 coculture 
supernatants revealed that MDC1 indeed acted as a strong LRA in an SEB antigen-dependent 
manner (Figure 7A; MDC1 alone vs. MDC1 + SEB, P ˂ 0.05), as did PGE2-DC (PGE2-DC alone 
vs. PGE2-DC + SEB, P ˂ 0.05) (424).   As expected, significant differences in transcription of 
proviral DNA were also observed between positive (anti-CD3/CD28) and negative (SEB) 
experimental controls (P < 0.01) and between SEB vs. DC + SEB conditions (SEB vs. MDC1 + 
SEB, P < 0.05; SEB vs. PGE2-DC, P < 0.01).   No significant differences in LRA activity between 
anti-CD3/CD28 and DC + SEB stimulation or between SEB and DC alone conditions were 
detected.   Importantly, MDC1 and PGE2-DC also did not differ in their abilities to mediate 
antigen-dependent HIV-1 latency reversal (Figure 7B), which becomes most apparent when 
normalizing the data based on mRNA expression levels above (LR+) or below the limit of 






Figure 7. Influence of antigen presentation on DC-mediated HIV-1 latency reversal in CD4+ T cells 
A, B) Differentially polarized DC were cocultured with autologous CD4+ T cells in the presence or absence of 
SEB antigen. Cell culture supernatants were analyzed by qRT-PCR for HIV-1 RNA at day 7. P values comparing 
viral RNA levels were determined by multilevel mixed-effects tobit regression analyses. Error bars indicate mean 
± SEM. *P˂0.05 and **P˂0.01. C) Latency reversal scores based on data represented in (A). LR+, latency 












However, to be clinically relevant, latency reversal strategies in HIV-infected individuals 
must be implemented under the administration of ART in order to prevent new infection events.  
As a proof of principle we repeated the DC/SEB-mediated LR experiments conducted in Figure 4 
in the presence or absence of the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz 
(EFV).  NNRTIs inhibit reverse transcription through an allosteric mechanism that involves 
noncompetitive binding to HIV-1 reverse transcriptase (RT) at a site adjacent to the DNA 
polymerase active site (485).  qRT-PCR analysis for both cell-associated (Figure 8A) and 
extracellular virion-associated (Figure 8B) HIV-1 RNA showed increased MDC1/SEB LRA 
activity compared to PGE2-DC/SEB reactivation, which was reproduced in the presence of EFV, 
albeit at lower levels.  These findings indicate that DC-mediated LR is achievable in the presence 
of antiretroviral therapy.  Furthermore, because MDC1 exhibited both higher CTL priming 
capacity (Figure 5) and the ability to reactivate latent HIV-1, this DC type was implemented in 













Figure 8. Antigen-loaded DC facilitate HIV-1 latency reversal in the presence of ART 
SEB-loaded, differentially polarized DC were cultured with autologous CD4+ T cells in the 
presence or absence of efavirenz. A) Cells and B) cell culture supernatants were analyzed by qRT-
PCR for HIV-1 RNA at day 7. Representative of one donor.    
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4.3 Role of CD40/CD40L interaction in MDC1-mediated ‘kick’ of latent HIV-1 
DC crosstalk with CD40L+ TH cells plays a critical role in the induction and survival of long-term 
CTL responses (458, 486-488).  Because we previously showed that MDC1 are particularly 
sensitive to CD40L signaling (385), and that this CD4+ T cell-derived ‘helper’ factor is required 
for effective MDC1-mediated in vitro priming of de novo CTL responses (Figure 5B) (424), we 
wanted to determine if CD40/CD40L cross-talk between the MDC1 and CD4+ T cells was playing 
a role in MDC1-mediated HIV-1 latency reversal.  Of note, CD40:CD40L ligation is required for 
optimal induction of polarizing signals (signal 3) that promote development of either TH1 or TH2 
cells capable of pathogen-specific immune responses through triggering of NF-κB signaling (489-
492).  As the PKC agonist and disulfiram classes of pharmacological LRAs operate through this 
mechanism to induce transcription of latent HIV-1 (155, 171, 178, 179, 493-496), we reasoned 
that CD40:CD40L interaction might play a role in our model of MDC1-mediated latency reversal.  
Indeed, we found that blocking CD40/CD40L interaction strongly decreased the effectiveness of 
MDC1-mediated LR (424).  The impact of this CD40L signaling inhibition on MDC1-mediated 
LR was clearly evident when analyzing the activated CD4+ T cells by flow cytometry, where the 
addition of an anti-CD40L blocking antibody resulted in a marked inhibition of CD4 
downregulation (87.7% ± 3.1%, P ˂ 0.05; Figure 9A and B), a phenomenon that occurs with HIV-
1 protein translation (497).  As expected, this inhibition of CD4 downregulation by addition of the 
CD40L blocking antibody was associated with abrogation of intracellular p24 expression (90.8% 
± 7.0%) (Figure 9A, C; P ˂ 0.05) induced in autologous CD4+ T cells, and with the reduction in 
HIV-1 RNA content in day 7 coculture supernatants measured by qRT-PCR (Figure 9D, 94.1% ± 
6.1% inhibition) (424).  Importantly, the addition of an isotype control antibody to the MDC1/T 
cell cocultures had no significant impact on the induced changes in CD4 expression or HIV-1 
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expression resulting from LR (Figure 9A-D).  Taken together, these data support the required 
involvement of cognate antigen-driven bidirectional signaling events between MDC1 and antigen-












Figure 9. MDC1-mediated latency reversal requires CD40/CD40L interaction 
DC1 were cocultured with autologous CD4+ T cells and SEB to induce HIV-1 LR, in the presence or absence of 
CD40L blocking antibody. A) Representative flow cytometry plot of day 15 cultures. Downregulation of CD4 
expression (red gate) corresponds with increased expression of p24 in the absence of CD40L blockade. Red histogram 
peak corresponds with p24 expression of CD4 downregulated population. B, C) Graphical representation of CD4 
downregulation (B) and p24 expression (C) of populations described in (A); n = 5. D) Day 7 cell coculture supernatants 
were analyzed by qRT-PCR for HIV-1 RNA; n = 3. Differences between MDC1/SEB-mediated LR in the absence or 
presence of CD40L blocking antibody were compared by Wilcoxon matched-pairs signed-ranks test. Error bars 
indicate mean ± SEM. *P˂0.05. 
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4.4 CMV and HIV-1 antigen-driven reactivation of latent HIV-1 by MDC1 
We have shown that MDC1-mediated transcription of HIV-1 DNA (Figure 7) and subsequent 
translation of p24 (Figure 9A, C) are both dependent on the presence of SEB superantigen and on 
CD40/CD40L signaling (424).  However, to simulate a clinically relevant method of HIV-1 LR, 
we posited that the inclusion of common viral MHC class II antigens as part of our MDC1-based 
therapeutic could promote interaction with CD40L expressing CD4+ T helper (TH) cells, to both 
provide immune ‘help’ for MDC1-mediated induction of HIV-1-specific CTL responses and to 
facilitate MDC1-mediated exposure of viral antigen-specific CD4+ T cells harboring latent HIV-
1. 
In choosing which viral antigens to incorporate in our model of MDC1-mediated LR, we 
considered previous findings that a significant pool of latently infected CD4+ T cells are HIV-1-
specific (498, 499).  As such, an HIV-1-based vaccine or LRA construct could potentially 
reactivate this population while also facilitating the ‘kill’ through CTL priming.  We also 
considered the fact that approximately 95% of HIV-1-infected individuals are coinfected with 
CMV (500), in whom CMV-specific CD4+ T cell memory inflation occurs (501), with some having 
greater than 25% of their T cells specific to CMV (502).  To test these findings in our cohort of 
MACS participants, we cocultured CMV antigen-loaded MDC1 with autologous peripheral blood 
lymphocytes (PBL) for expansion and characterization of CMV-specific T cell responses by flow 
cytometry (Figure 10).  Indeed, at baseline there was already a substantial number of T cells 
responsive to CMV antigen that could be generated by non-specific culture expansion (6.38%), 
and a striking percentage of CMV-specific T cells that could be specifically expanded (36.9%) 
with CMV antigen-presenting MDC1, based on coexpression of CD107a and IFN-γ.  Therefore, 
we hypothesized that inclusion of heterologous CMV antigen would effectively promote MDC1 
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interaction with CD4+ TH cells to facilitate ‘help’ for HIV-1-specific CTL induction and to induce 












Figure 10. Large percentage of T cell repertoire in HIV+ individuals is CMV-specific 
MDC1 alone or MDC1 loaded with CMV pp65 15-mer peptides were cocultured for 15 days with 
autologous PBL for expansion and characterization of antigen-specific CTLs. Peptide restimulated 
cells were assayed by flow cytometry for expression of CD107a and IFN-γ. 
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We tested MDC1 alone or loaded with CMV pp65, HIV-1 Gag, or influenza A virus M1 
protein (representing a common, non-persistent viral antigen) for their ability to induce latency 
reversal in autologous CD4+ T cells (Figure 11).  We found that MDC1-mediated LR was antigen-
dependent, with CMV and HIV-1 antigen having notable LR activity, while influenza virus antigen 
did not (Figure 11B-E) (424).  MDC1/CMV- and MDC1/HIV-1-mediated increases in 
extracellular virion-associated HIV-1 RNA were significantly greater than those induced by 
MDC1 alone (Figure 11B; P ˂ 0.01 and P ˂ 0.001, respectively).  Importantly, MDC1 presenting 
either CMV or HIV-1 antigen exposed latent HIV-1 cellular reservoir targets, identified by a 
marked downregulation in CD4 expression (Figure 11D) that corresponded to increases in 




Figure 11. CMV and HIV antigen presentation drive MDC1-mediated HIV-1 latency reversal 
A) MDC1 were loaded with either CMV pp65, HIV-1 Gag, or influenza M1 antigen and tested for their ability to 
induce LR in autologous CD4+ T cells. B) Culture supernatants were assayed by qRT-PCR for detection of HIV-1 
RNA at day 7. C) Representative flow cytometry plots of p24 expression of day 20 cocultures, gated on total CD4+ T 
cells. D) Graphical representation of MDC1/antigen-induced CD4 downregulation in cocultures described in (C), as 
measured by flow cytometry. E) Expression of p24 expression in cell populations detailed in (C). P values comparing 
viral RNA levels were determined by multilevel mixed-effects tobit regression analyses. Error bars indicate mean ± 
SEM. *P˂0.05, **P˂0.01, and ***P˂0.001. 
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4.5 MDC1-induced CTL effectively kill MDC1-exposed CD4+ T cell targets harboring 
replication-competent HIV-1 
MDC1 loaded with autologous HIV-1 Gag peptides were used to induce antigen-specific CTL 
(Figure 12A), as determined by flow cytometry analysis for antigen-induced expression of CD107a 
and IFN-γ (Figure 12B) and by IFN-γ ELISPOT (Figure 12C).  Antigen-induced downregulation 
of CD8 expression, a characteristic previously shown to be associated with enhanced cytolytic 
capacity (418, 503), was evident along with high expression of CD107a and IFN-γ in the CTL 
generated ex vivo using HIV-1 antigen-presenting MDC1 (Figure 12B) (424).  Also, the CTL 
responses induced by MDC1 were broadly reactive to a range of individual Gag 9-mer epitopes 




Figure 12. MCD1 induce broadly reactive HIV-1-specific CTL 
A) MDC1 priming model for generation of autologous HIV-1-specific CTL. MDC1 loaded with HIV-1 Gag p17/p24 
overlapping 18-mer peptides were cocultured with autologous CD8+ T cells in the presence of IL-2 and IL-7, with 
or without the addition of either CD40L-transfected J588 cells or rhCD40L. T cell cultures were restimulated with 
autologous MDC1 loaded with 9-mer peptides corresponding to the viral antigens used in the initial stimulation.  
CTL activity was assessed by antigen-specific readout assays between days 20-24. B) MDC1 induced broadly 
reactive antigen-specific autologous CTL as determined by flow cytometry staining for CD107a and IFN-γ. C) 
Polyclonal IFN-γ responses to individual Gag 9-mer epitopes by MDC1-induced CTL described in (B). 
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Next, HIV-1 Gag peptide-loaded CD4+ T cells or p24-expressing target cells generated in 
Aims 1.1b and 2b by MDC1-mediated latency reversal were cocultured with the HIV-specific 
autologous CTL at increasing effector-to-target ratios to test for antigen-specific targeting of the 
latent reservoir (Figure 13).  
 
Figure 13. Model of kill assays for determination of antigen-specific elimination of the latent reservoir by 
autologous CTL 
 
A) CD4+ T cells were labeled with CellTrace™ dye (violet) or CFSE (green) for use as target cells.  CFSE-labeled 
cells were additionally loaded with relevant HIV-1 Gag 9-mer peptides. Cells were mixed in equal numbers and 
coincubated for 18 hours with MDC1-induced autologous CTL at various E:T ratios. Antigen-specific killing of HIV-
1 peptide-loaded CD4+ T cells (green) was calculated based on relative changes in the percentages of viable 
differentially colored target cells. B) HIV-1 latency reversal was induced by MDC1 and SEB or antigen in CD4+ T 
cells. Target cells (T) were coincubated with autologous MDC1-induced effector CTL (E) at various E:T ratios for 18 
hours to assess target killing or 8 days to assess suppression of virus production. CTL-induced target killing was 
measured by loss of HIV-1 Gag p24-expressing target cells using flow cytometry. CTL-induced viral suppression was 




The antigen-specific killing capacity of these CTL was initially tested by coculturing them 
overnight with differentially labeled Gag 9-mer peptide antigen-loaded (CFSE-labeled, green) or 
antigen-negative/control (CellTrace™ violet-labeled) autologous CD4+ T cell targets.  Selective 
elimination of the antigen-loaded target cells was evident by flow cytometry analysis (Figure 14A, 
B) (424).  In addition, compared to autologous HIV-specific CTL, control CTL generated using 
MDC1 cultured in the absence of HIV-1 Gag peptides or with irrelevant control peptides 













Figure 14. Selective killing of HIV-1 antigen-expressing CD4+T cells by autologous MDC1-induced HIV-
specific CTL 
 
MDC1 generated from HIV-1-infected, ART-suppressed individuals were cultured with or without HIV-1 Gag 
peptides or with irrelevant control peptides (Influenza M1) and used to induce autologous CTL. A) CD4+ T cells were 
labeled with CellTrace™ dye (violet) or CFSE (green) for use as target cells.  The CFSE-labeled cells were 
additionally loaded with relevant HIV-1 Gag 9-mer peptides. Cells were mixed in equal numbers and coincubated for 
18 hours with MDC1-induced autologous CTL at various E:T ratios.  B) Antigen-specific killing of HIV-1 peptide-
loaded CD4+ T cells (green) was calculated based on relative changes in the percentages of viable differentially colored 
target cells. C) p24-expressing HIV-1-infected target cells (T) were coincubated with autologous MDC1-induced 
effector CTL at various E:T ratios for 18 hours. CTL-induced target killing was measured by loss of HIV-1 Gag p24-
expressing target cells using flow cytometry. D) Comparison of cytotoxic activity of HIV-specific CTL with CTL 
cultured in the absence of HIV-1 Gag peptides (Control CTL) in a representative donor (shown in A). Error bars 








More importantly, the LR activity of CMV and HIV-1 antigen-presenting MDC1 resulted in the 
effective exposure of HIV-1-infected target cells that were also recognized and efficiently 
controlled by MDC1/Ag-induced HIV-1-specific CTL in short-term cytotoxicity assays (75.4% ± 
14.3% killing), indicated by a dose-dependent decrease in p24-expressing CD4+ T cells (Figure 
15A, B) (424).  This pattern was consistent, regardless of the type of antigen used to induce MDC1-







Figure 15. MDC1-induced HIV-1-specific CTL effectively kill CD4+ T cells exposed by MDC1 
A) HIV-1 latency reversal was induced by MDC1 and SEB or antigen in CD4+ T cells. Target cells (T) were 
coincubated with autologous MDC1-induced effector CTL (E) at various E:T ratios for 18 hours. CTL-induced target 
killing was measured by loss of HIV-1 Gag p24-expressing target cells using flow cytometry. B) Summary of 5 
independent flow cytometry cytotoxicity experiments. Square symbols represent MDC1/SEB-induced target cells; 






Furthermore, CTL suppressed viral outgrowth from the infected cells in long-term cocultures, as 
indicated by a 74.4% ± 20.2% decrease in culture supernatant p24 (Figure 16) (424). 
 
 
Figure 16. HIV-1-specific CTL control viral outgrowth from HIV-1-infected CD4+ T cells 
A) HIV-1 latency reversal was induced in CD4+ T cells by MDC1 presenting SEB, CMV pp65, HIV-1 Gag, or 
influenza M1 antigen. Target cells (T) were cocultured with autologous MDC1-induced effector CTL (E) at various 
E:T ratios for 8 days. Culture supernatants were tested by p24 ELISA to measure CTL-induced viral suppression. 
Square symbols represent MDC1/SEB-induced target cells; circles indicate MDC1/viral antigen-induced targets. B) 








Recent studies have posited that CTL preferentially target cells containing defective HIV-
1 proviruses, which in effect act as decoy targets to prevent elimination of the true latent reservoir 
(59, 295, 296).  Therefore, we sought to determine whether MDC1-mediated LR activity unmasked 
cells harboring replication-competent virus that could be subsequently recognized and killed by 
the CTL.  To do so, culture supernatants collected from viral outgrowth assays at various effector-
to-target ratios (Figure 16) were subsequently cultured on TZM-bl reporter cells (72) for 
quantification of infectious HIV-1 (Figure 17).  Importantly, we found that MDC1 LR activity 
exposed those targets harboring replication-competent virus, whose elimination was apparent at 
even the lowest effector-to-target ratio (Figure 17A), resulting in 84.5% ± 6.7% suppression of 
replication-competent HIV-1 (Figure 17B) (424).  Thus, MDC1-primed HIV-1-specific 
autologous CTL were capable of eliminating HIV-1-infected cells harboring replication-
competent virus following their subsequent unveiling through the LR activity of MHC-class II 





Figure 17. HIV-1-specific CTL control MDC1-exposed targets harboring replication-competent HIV-1 
A) Model of TZM-bl assay for detection of replication-competent HIV-1. Culture supernatants collected from viral 
outgrowth assays (Figure 16) were spinoculated onto TZM-bl cell monolayers, cultured for 48 hours, and tested for 
chemiluminescence. B) Graphical compilation of individual experiments (RLU, relative light units). Solid symbols 
indicate HIV-1-infected participant samples; open symbols represent HIV-1-negative samples assayed in parallel. 
Square symbols represent MDC1/SEB-induced target cells; circles indicate MDC1/viral peptide antigen-induced 
targets. C) CTL-induced suppression of replication-competent HIV-1. Square symbols represent MDC1/SEB-induced 




We have shown that antigen-presenting MDC1 are capable of inducing both HIV-1 latency 
reversal in infected CD4+ T cells isolated from ART-treated HIV-1+ MACS participants, and HIV-
1 antigen-specific CTL responses that can effectively kill the MDC1-exposed HIV-1-infected 
targets (Figure 18) (424).  This MDC1-mediated ‘kick’ was found to be antigen-dependent, and 
bidirectional signaling events between the MDC1 and CD4+ T cells involving the CD40/CD40L 
signaling pathway contributed to this process (424).  Other studies have explored the LRA 
potential of immature DC using in vitro models of HIV-1 latency with infected immortalized cell 
lines (448, 452), through in vitro establishment of HIV-1 latency in primary CD4+ T cells of 
uninfected donors (447), or by addressing their nonspecific impact on in vitro pre-expanded 
polyclonal-activated T cells (446).   However, to our knowledge the present study is the first to 
demonstrate, in a natural setting of chronic HIV-1 infection, the effective, clinically relevant use 
of autologous mature DC that are specifically programmed to both mediate ex vivo LR in freshly 
isolated CD4+ T cells derived from individuals undergoing successful ART, and to induce effector 
cells capable of recognizing and eliminating the infected cells (424).  Our current data imply that 
a component of the HIV-1 reservoir is contained within the pool of both CMV- and HIV-1-specific 
CD4+ T cells.  Importantly, our study was limited to only a small number of viral antigen sources, 
and to only one target protein antigen for each of the respective viruses tested. Therefore, the levels 







Figure 18. MDC1: the all-in-one ‘kick and kill' tool 
MDC1 induce antigen-specific CD8+ and CD4+ T cell responses through presentation of antigenic peptides in the 
context of (1) MHC class-I and (2) MHC class-II molecules, respectively (signal 1) , along with costimulatory factors 
including CD80 and CD86 (not shown, signal 2). Responding CD4+ T cells subsequently provide MDC1 with the 
feedback hyperactivating ‘helper’ signal CD40L (3), necessary for MDC1 release of IL-12p70 (4), which then 
promotes expansion and differentiation of CD8+ HIV-1-specific effector CTL (5). Activation of CMV and HIV 
antigen-responsive CD4+ T cells harboring latent HIV-1 (6) results in HIV latency reversal (7), with HIV-1 proteins 
being transcribed and expressed as surface antigen (8). As a result, exposed infected cells harboring replication-







number and selection of antigens had been optimized.  This is especially true when considering 
antigen-specific CMV immunity, where CD4+ T cell responses to pp65 and IE-1 protein antigens 
comprise less than 12% of total CD4+ T cell responses to CMV in coinfected individuals (502).  
As CMV is one of the largest and most complex viruses, with a genome encoding over 200 open 
reading frames (504), our study has room for optimization through incorporation of other CMV 
antigens that might enhance the effectiveness of our MDC1-based LR strategy.  Nevertheless, our 
study demonstrates, as an important proof of principle, the potential that HIV-1 LR can be achieved 
to expose cells infected with replication-competent virus for CTL elimination, in both a safe and 
directed antigen-specific fashion. 
Previous studies in HIV-1-/CMV-coinfected individuals indicate that HIV-1-specific CD4+ 
T cells are preferentially infected and depleted by HIV-1 (499, 505), and that a portion of latently 
infected cells that remain during ART are indeed HIV-1-specific (498).  However, in contrast to 
our findings, it has been reported that CMV-specific CD4+ T cells are less susceptible to HIV-1 
infection in vivo (506).  In spite of this, a large body of data exists to support the notion that CMV 
antigen-specific CD4+ T cells, in particular, likely contribute to a sizeable portion of the latent 
HIV-1 cellular reservoir.  For example, CMV infection is frequent in HIV-1-infected individuals, 
with a seroprevalence of approximately 95% (500).  Furthermore, CMV occupies an inflated 
proportion, on average 10%, of memory T cell responses in healthy individuals, and CMV-specific 
CD4+ T cells persist at high levels in HIV-1- and CMV-coinfected individuals (501, 504, 507, 
508), with greater than 1 out of 4 of the total number of CD4+ T cells in peripheral blood being 
CMV-specific in some individuals (502).  Subclinical CMV replication often occurs in the mucosal 
and peripheral tissues of HIV-1-infected individuals, contributing to T cell dysfunction, impaired 
immune recovery, and chronic immune activation during ART (509-512).  In these environments, 
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CMV hijacks human cytokine/chemokine signaling to enhance inflammation, in turn augmenting 
its own replication (513).  Consequently, recruitment of target cells to sites of inflammation that 
are also major sites of HIV-1 persistence, such as gut and other lymphoid tissues, creates a 
favorable environment for reservoir seeding (514-517).  Recent evidence supporting this scenario 
was provided by a study of ART-suppressed individuals in whom CMV replication in the gut was 
associated with inflammation, mucosal barrier damage, and microbial translocation (514).  
Manipulation of HIV-1 coreceptor expression by CMV could also serve as a mechanism for 
establishment of the latent reservoir in susceptible target cells.  For example, CMV upregulates 
CCR5 expression on newborn umbilical cord blood central memory CD4+ T cells that could 
facilitate in utero transmission of HIV-1 (518).  In addition, in vitro studies demonstrate the ability 
of CMV to manipulate AP-1 and NF-κB signaling for induction of HIV-1 gene expression in 
infected bystander cells through direct transactivation of the HIV-1 LTR (519-522).  Each of these 
mechanisms could potentially lead to enhanced HIV-1 infection of target cells in CMV-coinfected 
individuals.  
Once established, the latent HIV-1 cellular reservoir could also be subject to CMV-
mediated proliferation or clonal expansion.  Proliferation of HIV-infected cells could occur in 
response to persistent CMV-derived antigenic stimulation, potentially leading to 
compartmentalization of HIV provirus within CMV-specific CD4+ T cells (516).  In support of 
this theory, cross-sectional studies have shown a correlation between CMV replication in blood 
and semen and higher levels of HIV-1 DNA in both ART-naïve and ART-suppressed individuals 
(523, 524).  In a related longitudinal study, CMV replication in PBMC of men initiating early ART 
was associated with delayed decay of HIV-1 DNA reservoirs (517). Furthermore, proviral and 
integration site analyses in ART-suppressed individuals have implicated clonal expansion of 
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latently infected CD4+ T cells as a major mechanism of HIV-1 persistence (25, 37, 41, 47, 525), 
and recent findings estimate that these expanded clones comprise 50-60% of the latent HIV-1 
reservoir (38, 60, 63).  Of note, in a study of 15 HIV-1-infected patients who underwent 
myeloablative chemotherapy for CMV- and Epstein-Barr virus (EBV)-associated malignancies, 
increases in HIV-1 DNA were preferentially found in CMV- and EBV-specific CD4+ T cells after 
immune reconstitution (526).  It is also possible that self-renewal of stem cell memory T cells 
(TSCM) may contribute to homeostatic proliferation of the latent HIV reservoir (527).  This subset 
of memory T cells plays a significant role in the maintenance of long-term immunological memory 
and contains the most copies of integrated provirus per cell in HIV-1-infected individuals (527).  
Finally, CMV-infected individuals possess functional CMV-specific TSCM cells that could promote 
expansion of the HIV-1 reservoir in CMV/HIV-1-coinfected persons through homeostatic 
proliferation, even during ART (528). 
Coincidentally, expanded CMV-specific CD4+ T cells harboring latent HIV could be 
protected from elimination as a consequence of numerous immune evasion strategies that CMV 
has evolved.  CMV can not only inhibit cell surface HLA expression, but also produces decoy 
viral homologues of HLA class I molecules which protect it from NK cell immunosurveillance 
(529, 530).  Similarly, CMV hijacking of cell signaling pathways could also benefit HIV 
persistence in coinfected individuals.  Among these, IL-10 signaling is known to dampen 
proinflammatory immune responses and to promote a tolerogenic environment (531).  IL-10, 
which can be induced by HIV itself, has also been shown to inhibit HIV replication and latency 
reversal in vitro (532-534).  Importantly, CMV encodes viral homologues of human IL-10 (hIL-
10) that produce the same immunosuppressive effects, which are further intensified by CMV’s 
ability to upregulate hIL-10 expression during infection (535, 536).  Furthermore, CMV-mediated 
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manipulation of PD-1 signaling may play a role in HIV-1 persistence during coinfection.  PD-1 
signaling on newly HIV-infected CD4+ T cells has been proposed as a mechanism by which these 
cells transition toward a state of persistence to escape activation-induced cell death (314, 537).  In 
support of this theory, PD-1-expressing CD4+ T cells contain high levels of proviral DNA, and 
PD-1 expression is positively correlated with plasma viremia (314, 538).  Relevant to these 
findings, a recent study of ART-suppressed men demonstrated an association between seminal 
CMV shedding and increased PD-1 expression on CD4+ T cells (512).  Finally, CMV could 
interfere with innate cellular sensors that function to trigger apoptosis of HIV-infected cells before 
viral integration (539, 540).  CMV encodes two proteins that block apoptosis through either 
inhibition of cytochrome C release from mitochondrial membranes or interference with activation 
of caspase-8 (541, 542).  In these ways, CMV could contribute to enhanced seeding of the latent 
reservoir during acute HIV infection (516).  Thus, mounting evidence suggests that CMV 
coinfection could contribute to establishment and maintenance of the HIV-1 reservoir. 
Conversely, Casazza et al. cite several factors that render CMV-specific CD4+ T cells less 
susceptible to HIV infection (506).  Based on previous findings in coinfected individuals that HIV-
specific CD4+ T cells are preferentially infected and depleted by HIV, CMV-specific CD4+ T cells 
are often present in late stage HIV infection, and CMV-related disease does not occur until end 
stage AIDS, the group postulates that CMV-specific CD4+ T cells are protected from HIV infection 
in vivo (499, 505, 543-545).  The proposed mechanism underlying this protection involves 
increased autocrine production of β-chemokines MIP-1α and MIP-1β by CMV-specific CD4+ T 
cells upon stimulation by cognate antigen (506).  Binding of β-chemokines or RANTES to CCR5 
blocks HIV infection of CMV-specific CD4+ T cells by either steric hindrance of CD4 receptor 
binding or downregulation of CCR5 coreceptor expression (546-549).  Based on their finding that 
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HIV infection of CMV-specific CD4+ T cells was relatively low compared to infection of tetanus 
toxoid- and C. albicans-specific cells despite neutralization of β-chemokines, Hu et al. suggested 
postentry restriction as a potential mechanism for resistance of CMV-specific cells to HIV 
infection (550).  Corroborating microarray data revealed selective upregulation of type I IFN 
response genes, as well as TRIM5 and TRIM22 restriction factors in CMV-specific CD4+ T cells.  
In addition, unlike HIV-specific CD4+ T cells, more mature CMV-specific CD4+ T cells exhibit a 
phenotype of replicative senescence and therefore do not enter the cell cycle, which also limits 
HIV replication (196, 551-555). 
Although our study points to CMV- and HIV-1-specific CD4+ T cells as harboring latent 
provirus, it is likely that CD4+ T cells specific to other viruses that manifest as chronic infections, 
including EBV and herpes simplex virus, contribute to the latent reservoir as well.  Given the 
relevance of the B cell follicle as a major tissue reservoir of HIV, and that EBV is B cell-tropic, 
we initially considered implementing EBV antigen in MDC1-mediated latency reversal 
experiments in Aim 2.  However, due to the aforementioned limitations of CD4+ T cell recovery 
from our chronically infected study participants, we had to restrict our study to the use of CMV, 
influenza, and HIV-1 antigens.  Moreover, while we did not observe influenza antigen-mediated 
LR ex vivo, others have documented increases in cell-associated HIV-1 RNA expression in HIV-
1-infected individuals receiving influenza vaccination during suppressive ART (556, 557).  
However, deep sequencing studies pre- and post-vaccination suggested nonselective induction of 
proviral expression from a broad pool of HIV-1-infected bystander cells (557).  While the LR 
demonstrated in our study was antigen-driven, we do not rule out the possibility that proviral 
reactivation could reflect nonspecific bystander effects of a potent MDC1-mediated antigen-
specific response, rather than a direct impact on an antigen-specific reservoir. 
107 
Recent in vivo studies utilizing TLR7 and TLR9 agonists to promote HIV-1 LR have shown 
promise (192-194), and are currently being studied in human trials (http://www.clinical trials.gov 
NCT02858401, NCT03060447, NCT03837756).  However, the mechanisms of how these innate 
immune receptor activators lead to reactivation of the latent reservoir have yet to be fully 
elucidated.  Evidence from human and nonhuman primate studies implicates the IFN-α-producing 
plasmacytoid DC (pDC) as being an important cellular component in this process (191, 192, 194).  
It is worth noting that the combination of factors used in the maturation and generation process of 
the specialized antigen-presenting type-1 programmed MDC1 used in our study, which includes 
IFN-α, IFN-γ, and the TLR3 agonist poly (I:C), was designed to mimic maturation events expected 
to occur as a result of DC crosstalk with responding IFN-α-producing pDC and IFN-γ-producing 
NK cells during the early stages of a successful antiviral immune response (383, 407).  The factors 
produced by these early immune responders programs the maturing DC to be hyper-responsive to 
subsequent signaling factors they receive during antigen cognate interactions with CD4+ TH cells.  
Although the underlying mechanisms of MDC1-mediated LR observed in our study have 
not been fully identified, our findings do indicate that bidirectional cross-talk between the MDC1 
and the CD4+ T cells during cognate antigen-driven interaction involving the CD40/CD40L 
signaling pathway contributed to the noted LR activity (424).  Based on gene chip analysis of 
CD40L-activated MDC1 that revealed upregulations in galectin-9, TNF-α, and IL-15 mRNA (data 
not shown), all of which have been implicated as potential inducers of LR (212, 221, 446), these 
factors warrant further investigation.   
Furthermore, targeting the true latent reservoir poses numerous challenges with regard to 
antigen delivery by a DC vaccine in vivo to certain sites that are anatomical sanctuaries of HIV-1, 
such as B cell follicles (322).  It is well documented that secondary lymphoid organs (SLOs) such 
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as the spleen, lymph nodes, and gut-associated lymphoid tissue (GALT) are the major sites of HIV 
replication.  B cell follicles found within SLOs contain numerous phenotypically and functionally 
distinct cell types.  Whereas CTLA4+CD4+ T cells are the primary targets of HIV infection within 
the T cell zone of lymph nodes (558), the T follicular helper (TFH) and T follicular regulatory (TFR) 
subsets that reside within the B cell follicle are not only more susceptible to infection (317-319), 
but harbor the highest concentration of HIV-1 RNA in both untreated chronic SIV and HIV 
infection prior to the development of AIDS (321, 559, 560).  Indeed, follicular CD4+ T cells are 
30-40 times more likely to contain HIV RNA than extrafollicular (EF) CD4+ T cells (320, 321).  
The TFH subset responsible for germinal center (GC) reactions, affinity maturation, class 
switching, and memory B cell differentiation (561) is most prevalent within the B cell follicle 
(324).   In vivo infection of TFH cells may be influenced by their close spatial relationship with 
follicular dendritic cells (FDC) carrying HIV immune complexes (IC), which accounts for their 
increased susceptibility to FDC-bound IC-mediated infection compared to EF CD4+ T cells (562).  
TFH cells are further subdivided into germinal center TFH (GC-TFH) and non-germinal center TFH 
(non-GC TFH) subsets expressing high and intermediate-to-low levels of PD-1, respectively.  The 
PD-1hi GC TFH cell subset is more susceptible to infection, and thus GCs contain the greatest 
concentration of HIV RNA+ cells within the B cell follicle (318).  Interestingly, PD-1+ memory 
TFH were recently reported to be the major reservoir of replication-competent provirus in ART-
suppressed individuals (55).  However, compared to EF, TFH, and EF TREG subsets, the highest 
percentage of HIV RNA+ cells is found within the recently identified TFR subset (319, 563-565).  
This population modulates TFH functions to prevent autoimmunity (565), but HIV-induced TFR 
expansion and increases in expression of regulatory factors by TFR enhance this effect, potentially 
contributing to TFH dysfunction during chronic infection (566).    Notably, changes in the frequency 
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and function of TFH and TFR that impact somatic hypermutation are thought to contribute to the 
inability of most HIV-infected individuals to produce bNAb (567, 568).  
Despite decreases in the frequency of follicular HIV RNA+ cells during ART, these cells 
are still detectable (118, 569, 570).  Furthermore, HIV-IC bound to the surface of FDC present in 
LN, GALT, and spleens constitute a major reservoir (571-573) of long-lived, infectious virus even 
in the presence of neutralizing antibodies (562, 574, 575).  Importantly, infected EF CD4+ T cells 
are subject to CTL-mediated elimination, but latently infected cells within the follicle are protected 
from CTL control, as most CTL do not express the follicular homing receptor CXCR5 (320).  In 
addition to limitations of trafficking, some reports suggest that follicular CXCR5+CCR7- CD8+ T 
cells are less cytolytic than CXCR5-CCR7- extrafollicular CTL, expressing regulatory or exhausted 
phenotypes, lower levels of perforin, and decreased polyfunctional cytokine responses (311, 325, 
326).  Conversely, other studies document that although less frequent, the CXCR5+CD8+ T cell 
population exhibits increased cytolytic potential compared to CXCR5-CD8+ T cells, including 
higher levels of perforin and IFN-γ production and a less exhausted phenotype (311, 327).  Thus, 
the mechanisms governing CTL trafficking and cytolytic activity within B cell follicles are largely 
unknown.  Novel strategies to address barriers to CTL targeting of this compartment are being 
explored, including temporary disruption of the B cell follicle with depleting antibodies (anti-
CD20/rituximab), blockade of T and B cell interactions using anti-CD40L, and therapeutic 
vaccination with engineered CTL or chimeric antigen receptor T cells expressing CXCR5 (54, 
324).  Treatment with recombinant IL-15 or the IL-15 superagonist ALT-803 has also been 
proposed as a method of enhancing follicular CTL function, as both have been shown to augment 
HIV-specific CTL responses in addition to their latency reversal properties (212, 324).   
Furthermore, ALT-803 has advanced to a clinical trial in ART-treated HIV-infected individuals 
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(http://www.clinical trials.gov NCT02191098).  Another elegant strategy involves the use of 
bispecific antibodies targeting CD3 and HIV gp120 that have the dual capacity to act as LRAs and 
to facilitate ADCC in gp120-expressing cells, as well as induce killing of HIV-infected cells by 
follicular CTL (311, 330).  As such, lymph node-homing CXCR5+CD8+ T cells could be 
transduced to produce these antibodies in order to facilitate killing of latently infected cells within 
the B cell follicle (324).  Though not addressed in this study, the question of whether MDC1 
express CXCR5 is clinically relevant to latency reversal approaches targeting the B cell follicle 
and warrants investigation.  MDC1 could also be transduced to express CXCR5 to facilitate 
follicular homing in vivo.  In addition to these strategies, the LRA potential of antigen-presenting 
B cells or other immune cells should be explored as potential components of a targeted 
immunotherapy.  Inextricably linked, all of these factors highlight the significance of the B cell 
follicle in HIV persistence and necessitate its careful consideration in HIV cure strategies.  
Nonetheless, the results presented here provide strong rationale for the incorporation of MDC1 in 
a dual therapeutic approach for both the ‘kick’ and the ‘kill’ of latent HIV-1. 
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6.0 IMPLICATIONS TO PUBLIC HEALTH 
In December 2013, the UNAIDS 90-90-90 initiative set ambitious targets to scale up global HIV 
treatment beyond 2015 as a call to end the AIDS epidemic by 2030 (576).  This three-part target 
proposed that by 2020, 1) 90% of all individuals living with HIV will be diagnosed, 2) 90% of all 
people diagnosed with HIV will receive sustained antiretroviral therapy, and 3) 90% of all ART-
treated individuals will achieve viral suppression (576).  At the end of 2017, 75% of people living 
with HIV knew their status, 79% of those diagnosed were receiving ART, and 81% of individuals 
accessing treatment had achieved viral suppression (577).  Despite these successes, coverage gaps 
in treatment and resources still affect entire regions and populations.  Progress in meeting the 2020 
targets is falling behind in western, central, and North Africa; eastern Europe, central Asia, and 
the Middle East (577).  Among factors contributing to this lack of progress is the increased risk of 
HIV infection among young women in areas of high HIV prevalence, such as Africa and the 
Caribbean (3).  In addition, barriers to traditional HIV testing services continue to impact 
adolescents, men, and key populations, including people who inject drugs, men who have sex with 
men, sex workers, transgender people, and prisoners (3).  Lack of political commitment, stigma 
and discrimination, HIV criminalization, and lack of access to affordable care are major factors 
undermining progress toward the 90-90-90 targets (3, 577).  Thus, given the logistical and 
economic challenges in delivering optimal, lifelong treatment to the more than 35 million people 
living with HIV, there is heightened interest in finding an effective method of controlling the virus 
in the absence of ART (187).  According to the goals set forth in the International AIDS Society 
global scientific strategy of 2016, development of a safe, affordable, and scalable HIV cure 
strategy is paramount (187).   
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Despite recent cases of what were initially considered functional HIV-1 cures, to date only 
one case of complete viral eradication in a patient, a ‘sterilizing’ cure (578), has been recorded.  
Also known as the ‘Berlin patient’, Timothy Ray Brown is an HIV-positive individual who 
underwent stem cell transplantation during chronic infection for acute myelogenous leukemia in 
2007 (579).  The stem cell donor was homozygous for the CCR5Δ32 mutation (580), which results 
in a truncated, nonfunctional variant of the CCR5 coreceptor, rendering carriers resisitant to 
CCR5-tropic HIV infection.  Five years post-transplant, neither HIV-1 RNA nor DNA could be 
detected in PBMC, lymph node, spinal fluid, or terminal ileum in the absence of ART (83).  In 
addition, Brown’s antibody and T cell responses to the virus had diminished, and replication-
competent HIV could not be cultured from PBMC (83).  However, plasma HIV RNA and rectal 
HIV DNA could be detected, albeit at levels lower than those typically observed in ART-
suppressed individuals, and were considered probable false positive results.  Though Brown is 
deemed to be clinically cured of HIV-1 infection, detection of residual viremia may also reflect 
persistent HIV, highlighting the need for more sensitive methods to quantify the latent reservoir.  
Nevertheless, the recent report of the ‘London patient’ provides new evidence that complete 
eradication of persistent HIV may be achievable (581).  As of March 2019, the HIV-positive man 
remains in HIV remission in the absence of ART, 19 months after receiving a bone marrow 
transplant for Hodgkin’s lymphoma from a CCR5-negative donor. 
Viral rebound in the absence of ART represents HIV replication from stable reservoirs 
(17), and trials implementing analytic treatment interruption (ATI) have revealed a correlation 
between total proviral DNA and time to viral rebound (582, 583).  Hence, current HIV-1 
eradication studies focus on the timing of viral rebound following ART cessation as a measure of 
reservoir reduction (83, 87, 579, 584).  Several cases of long-term control of HIV-1 replication in 
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the absence of ART, or ‘functional’ cures (578, 585), have been reported.  The ‘Boston patients’ 
underwent allogeneic stem cell transplants during ART, one for treatment of Hodgkin’s lymphoma 
and the second for diffuse B cell lymphoma and subsequent Hodgkin’s lymphoma (586).  Unlike 
the cases of Timothy Ray Brown and the ‘London patient’, stem cells were instead obtained from 
HIV-1-susceptible CCR5 wild-type donors (586).  Although virus was undetectable in peripheral 
blood and gut-associated lymphoid tissue (GALT) for years post-transplant and during ART, both 
chronically HIV-infected individuals experienced rebound viremia within 3-8 months of ATI, as 
measured by plasma HIV-1 RNA and cell-associated HIV-1 DNA (586).  In agreement with 
previous studies (582, 583), Henrich et al. suggested long-lived tissue reservoirs may have 
facilitated viral persistence and subsequent lack of virological control upon ART cessation in these 
patients.    
Results of the VISCONTI Study showed that ART initiation in HIV-infected individuals 
during acute infection decreased reservoir seeding in long-lived resting CD4+ T cells (587).  These 
post-treatment controllers (PTCs) lacked protective HLA alleles characteristic of elite controllers 
and strong HIV-specific CD8+ T cell responses, but were somehow able to maintain control of 
viremia for several years following ART interruption (587).  
Another example illustrating the impact of early ART on reservoir size and viral rebound 
is the case of the ‘Mississippi baby’ (588).  Born to an untreated HIV-infected mother, the infant 
received ART 30 hours after birth due to high-risk exposure.  Infection was confirmed by repeated 
detection of HIV RNA and DNA, and ART was administered until discontinued by the child’s 
mother after 18 months.  Although viremia remained below the level of detection for over two 
years following treatment interruption, viremic relapse occurred at 27 months (589, 590).  As 
observed in the ‘Boston patients’, lack of HIV-1-specific immune responses combined with the 
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presence of replication-competent virus in the ‘Mississippi baby’ confirms that a latent reservoir 
still persists in these individuals despite early ART (17).  
A final documented case of a functional HIV-1 cure is that of a perinatally infected child 
who received treatment early and remained in virological remission for over 12 years after ART 
interruption (591).  Although the infant received HIV prophylaxis for six weeks after birth, HIV 
DNA was detected at four weeks of age, prompting the initiation of ART at 3 months.  Suppressive 
ART was discontinued by the child’s family at approximately six years of age, and HIV RNA 
levels below the limit of detection, accompanied by stable CD4 counts, were maintained for over 
11 years (591).  Interestingly, the adolescent also exhibited characteristics similar to those reported 
in adult PTCs, including suboptimal HIV-specific CD8+ T cell responses (591). 
Due to the relative success of combination antiretroviral therapy (cART) since its advent 
in 1996 (4), HIV infection is now managed as a chronic condition.  Accordingly, one might argue 
that pursuit of a sterilizing, or even a functional HIV-1 cure is no longer warranted.  However, 
while current treatment regimens are more tolerable and less toxic (228), perturbations in lipid and 
glucose metabolism have been observed in individuals on long-term ART (592).  These metabolic 
imbalances manifest in numerous comorbidities that impact this aging population, including 
cardiovascular and liver disease, diabetes, and cancer (593-596).  Contributing to these conditions 
are residual immune activation and inflammation that persist even in individuals on successful 
ART, especially in those who fail to restore CD4+ T cell counts (597-599).  HIV-related systemic 
immune activation has been linked to immunosenescence, which also predisposes infected 
individuals to non-AIDS-defining comorbidities such as atherosclerosis and cardiovascular 
disease, neurodegeneration, and cancer (600).  Although ART has reduced the risk of death from 
HIV-1 infection, infected individuals are at greater risk of morbidity and mortality as a result of 
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these non-AIDS-related conditions than the general population (601-603).  Drug toxicities, the 
potential for developing drug resistant virus, and treatment adherence issues are additional 
challenges associated with lifelong ART (187).  All of these factors underscore the need to explore 
therapeutic alternatives that involve either durable control of viremia in the absence of ART or 
complete eradication of viral reservoirs. 
Findings of the current study have the potential to transform the functional HIV cure 
approach through implementation of a precise, DC-based immunotherapy that elicits potent 
effector responses to autologous viral antigens while exposing the HIV cellular reservoir for 
immune targeting by promoting antigen-driven latency reversal in responsive HIV-infected CD4+ 
T cells.  To date, the majority of ‘shock and kill’ strategies have focused on reactivation of proviral 
DNA using pharmacological LRAs, none of which have achieved reductions in the latent reservoir 
in over 15 completed clinical trials (121, 122).  HIV eradication trials have also revealed that the 
‘kill’ does not passively follow the ‘shock’ induced by current LRAs (122, 287), in part due to the 
numerous immunosuppressive effects of various LRAs on CTL function (159, 226, 297, 468, 470).  
These include increases in CD8+ T cell death and exhaustion marker expression, as well as 
decreases in CD3 expression and CD8+ T cell proliferation, IFN-γ production, and killing capacity 
(159, 226, 297).  Furthermore, HDAC inhibitors also negatively impact NK cell function (298).  
In contrast, DC-based therapies have proven to be safe (443) and well tolerated in clinical settings, 
and would serve as a more natural way to activate the HIV cellular reservoir.  To date, one of the 
most impressive HIV immunotherapy trials, reported by Garcia et al. (427), utilized DC pulsed 
with inactivated autologous HIV, which resulted in a significant decrease in HIV RNA setpoint 
and was associated with increased anti-HIV CD8+ T cell responses.  However, as with many other 
DC-based studies, including those previously used by our group (426, 442), the Garcia trial 
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implemented DC generation methods that yield IL-12p70-deficient DC (383, 385).  In an attempt 
to address this, Argos Therapeutics used a DC-based approach involving ex vivo genetic 
manipulation of DC via electroporation to deliver a constitutive CD40L helper signal to the DC, 
which failed as an immunotherapy for early and chronic HIV infections (435-437).  Perhaps 
explaining these results, we have shown that constitutive CD40L signaling results in a burst of IL-
12p70 production in vitro, but ultimately leads to IL-12p70-exhausted, TH cell-unresponsive DC 
(294).  Importantly, results from a clinical trial by our group unexpectedly demonstrated that 
delivery of a DC-based therapeutic HIV vaccine using inactivated autologous HIV as antigen was 
associated with unprecedented, increased viremia in ART-suppressed individuals (442).  However, 
because that clinical study was also not designed to address the use of DC as a therapeutic LRA, a 
number of questions regarding the roles of DC polarization and antigen presentation in in vivo LR 
were left unanswered.  
Because of their recognized superior potential to drive long-lived CTL responses from 
naïve T cell precursors (457, 458), the specialized type-1 polarized DC-based therapeutic platform 
(MDC1) used in the current study (424) has been successfully implemented with impressive results 
in cancer trials (368, 396, 429, 454-456) and is currently in early stages of FDA-approved phase I 
HIV clinical trials in Thailand (RV490/DC-03/SEARCH033) and Pittsburgh (DC-04) cohorts.  
This strategy exploits DC programming for timely production of IL-12p70 upon subsequent 
antigen-specific interaction with CD4+ TH cells to drive type-1 polarized immune responses (383, 
385, 410).  Both studies are designed to target only highly conserved HIV-1 epitopes using MDC1 
loaded with conserved HIV-1 peptide libraries as the vaccine, but differ from one another by 
studying acute (Thailand) and chronic (Pittsburgh) ART cohorts.  Findings of the current study 
have been incorporated in a grant proposal to enhance the study design of an already approved 
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MDC1-based clinical HIV trial in Brazil, setting it apart from the aforementioned MDC1 trials by 
adding CMV-associated MHC-class II peptide antigen as an immunotherapeutic.  Current and 
proposed trial arms are detailed in Figure 19.  The primary aims of the original phase I clinical 
study were to assess the safety and tolerability of an αDC1 (MDC1) therapy in participants 
receiving early ART (Fiebig 1-5), evaluate virologic and immunologic impacts of the αDC1 
therapy, and correlate these findings with alterations in GALT.  Primary endpoints of the original 
and proposed studies include safety and changes in plasma viral load, and CD4+ T cell setpoints 
following analytic treatment interruption (ATI).  The three arms of the original trial included 1) 
placebo control, 2) αDC1 loaded with inactivated autologous HIV, and 3) αDC1 loaded with 
inactivated autologous HIV, followed by temporary ATI.  The modified study employing CMV 
antigen will consist of 4 treatment arms: 1) αDC1 empty control; 2) αDC1 loaded with inactivated 
autologous HIV; 3) αDC1 loaded with CMV peptide; 4) αDC1 loaded with inactivated autologous 
HIV and CMV peptides.  All proposed treatment groups will include 10 participants per group 











Importantly, our study supports the concept that CMV-specific CD4+ T cells could harbor 
a prominent portion of the HIV latent reservoir. We hypothesize that this is based on persistent, 
low-level reactivation of latent CMV and consequent stimulation of CMV-specific, CD4+ memory 
T cells that become HIV-infected and preferentially survive as a quiescent HIV DNA reservoir.  
Thus, the use of CMV antigen in the proposed strategy can serve two important functions.  First, 
for the HIV ‘kill’ it will promote MDC1 interaction with CD4+ T cells that can provide the CD40L 
‘helper’ activation signal required to promote MDC1 IL-12p70 production and induction of long-
Figure 19. Brazil/USA αDC1-based HIV-1 immunotherapy trial 
A) Treatment groups of original (left) and proposed (right) αDC1 clinical trial. B) Timeline of study, 
therapy regimen, and sample collection schematic for the study participants; PVL, plasma viral load. 
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lived primary HIV-1-specific CTL responses (294, 383, 486-488, 604, 605).  Second, for the HIV 
‘kick’, this approach can facilitate the targeted unveiling of responsive CMV antigen-specific 
CD4+ T cells, which themselves could represent a large portion of the latent HIV reservoir.  As 
other CMV vaccine preparations are currently in clinical trials in HIV-negative individuals, we 
believe that a CMV peptide-based vaccine is a highly immunogenic formulation that is both safe 
and currently acceptable for human clinical use (606-608).  In the Brazilian cohort, this unique 
approach will test the dual capacity of the MDC1 therapeutic to facilitate HIV latency reversal and 
expose the viral reservoir, while concurrently boosting cellular immune effectors to kill the HIV-
infected cells.  Thus, information gained from these studies could lead to the durable control or 
cure of HIV-1 infection.   
Nevertheless, due to the numerous stakeholders in cure research, overcoming the 
challenges associated with either complete eradication of HIV or a functional cure will require 
multidisciplinary global collaboration that extends beyond biomedical research (187).  Due to the 
complexity and rapid evolution of cure science, research on science translation and public 
engagement will be critical to the success of cure strategies (187).  First, the perceptions of people 
living with HIV must be central in the design of cure approaches.  Serostatus is often a factor in 
decisions regarding the health and psychological well-being of these individuals, influencing not 
only sexual behaviors but social involvement (187).  As a result, their conception of HIV cure may 
directly influence their trust and engagement in HIV services and health care, willingness to 
disclose serostatus, and risk behaviors (187).  As demonstrated by examples of fraudulent and 
ineffective HIV ‘cures’ in sub-Saharan Africa (609), these beliefs could also determine the 
willingness of people living with HIV to participate in clinical trials and shape their perceptions 
of the benefits and risks of cure research (187).  Thus, research into the ethical, personal, 
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behavioral, and social implications of participation in cure research, as well as effective 
communication of the science and associated risks and benefits of HIV immunotherapies, must be 
a focus of cure strategies moving forward (187). 
Second, early engagement of stakeholders at multiple levels and standardized tools for 
measuring stakeholder involvement must be implemented to foster the success of cure efforts 
(610).  Stakeholders in cure research include but are not limited to individuals living with HIV, 
health care professionals and scientists, funding and regulatory agencies, public health authorities, 
civil society organizations, and pharmaceutical companies (187).  Collaboration between these 
diverse groups can also help prevent or mitigate potential failures of cure strategies (610). 
Equally important to the future success of HIV cure efforts is the equitable distribution of 
therapies among diverse trial participants in terms of sex, age, ethnicity, and other demographic 
characteristics (187).  Moreover, modeling research could provide scientists with information to 
help optimize clinical trials by predicting which individual or combination of cure approaches has 
the potential to achieve population-level effects (611).  In this regard, both affordability and cost-
effectiveness will be deciding factors, especially in resource-limited countries that have 
disproportionately high incidences of HIV infection and would benefit the most from a cure (612).  
Finally, determining the cost of an HIV cure and assigning responsibility for payment will be 
crucial considerations in the design of feasible interventions (187).  Despite all of these challenges, 
the ever-changing landscape of HIV research has produced promising therapeutic strategies that 
have the potential to cure a disease once considered a death sentence.  However, this goal will 
never be attainable as a result of scientific discovery alone, but only in conjunction with 
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